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Materials and Methods 
 
Unless otherwise stated, reactions were performed in flame-dried glassware under 
an argon or nitrogen atmosphere using dry, deoxygenated solvents. Solvents were dried by 
passage through an activated alumina column under argon. tert-Butyl 3-oxopiperazine-1-
carboxylate 1 was obtained from Combi-Blocks. Commercially obtained reagents were 
used as received. Chemicals were purchased from Sigma Aldrich/Strem/Alfa 
Aesar/Combi-Blocks and used as received.   
Reaction temperatures were controlled by an IKAmag temperature modulator. 
Glove box manipulations were performed under a nitrogen atmosphere. Thin-layer 
chromatography (TLC) was performed using E. Merck silica gel 60 F254 precoated plates 
(0.25 mm) and visualized by UV fluorescence quenching, iodine on silica, ninhydrin, or 
KMnO4 staining. SiliaFlash P60 Academic Silica gel (particle size 0.040–0.063 mm) was 
used for flash chromatography.  
Analytical SFC was performed with a Mettler SFC supercritical CO2 analytical 
chromatography system utilizing a Chiralpak IC column (4.6 mm x 25 cm) obtained from 
Daicel Chemical Industries, Ltd. with visualization at 254 nm. Reverse Phase Preparatory 
HPLC was performed with a Teledyne ISCO ACCQPrep HP125 preparative liquid 
chromatography system equipped with a RediSep Prep C18 5 µm column (20 x 250 mm).  
1H NMR spectra were recorded on a Varian Inova 600 MHz or 500 MHz 
spectrometer or a Bruker Avance HD 400 MHz spectrometer and are reported relative to 
residual CHCl3 (δ 7.26 ppm) or CH3OH (δ 3.31 ppm). 13C NMR spectra were recorded on 
a Varian Inova 500 MHz spectrometer or a Bruker Avance HD 400 MHz spectrometer and 
are reported relative to residual CDCl3 (δ 77.16 ppm) or CD3OD (δ 49.00 ppm). Data for 
1H NMR are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, 
sept = septuplet, m = multiplet, br s = broad singlet. Data for 13C NMR are reported in 
terms of chemical shifts (δ ppm). Some reported spectra include minor solvent impurities 
of water (δ 1.56 or 4.87 ppm), ethyl acetate (δ 4.12, 2.05, 1.26 ppm), methylene chloride 
(δ 5.30 ppm), acetone (δ 2.17 ppm), grease (δ 1.26, 0.86 ppm), and/or silicon grease (δ 0.07 
ppm), which do not impact product assignments.  
IR spectra were obtained using a Perkin Elmer Paragon 1000 spectrometer using 
thin films deposited on NaCl plates and reported in frequency of absorption (cm-1). High 
resolution mass spectra (HRMS) were obtained from an Agilent 6200 Series TOF with an 
Agilent G1978A Multimode source in electrospray ionization (ESI+), atmospheric 
pressure chemical ionization (APCI+), or mixed ionization mode (MM: ESI-APCI+). 
Optical rotations were measured with a Jasco P-2000 polarimeter operating on the sodium 
D-line (589 nm), using a 100 mm pathlength cell and are reported as: [α]DT (concentration 
in g/100 mL, solvent). Stereochemistry is assigned by analogy to previous results.1 
 
List of Abbreviations: An – Anisoyl, Boc – tert-Butyloxycarbonyl, BRSM – based on 
recovered starting material, Bz – benzoyl, CH2Cl2 – methylene chloride, Cbz – 
carboxybenzyl,  ee – enantiomeric excess, Et2O – diethyl ether,  EtOAc – ethyl acetate, 
IPA – isopropanol, LHMDS – lithium hexamethyldisilazide, MeCN – acetonitrile, MeOH 
– methanol, SFC – supercritical fluid chromatography, THF – tetrahydrofuran, TFA – 
trifluoroacetic acid, TLC – thin-layer chromatography. 
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Preparation of Known Compounds: Allyl cyanoformate was prepared according to the 
method of Weber.2 Phosphinooxazoline (PHOX) ligands (S)-L1, (S)-L2, and achiral 
GlyPhox  were prepared by methods described in our previous work.3 Di-benzoylated 
allylic alkylation substrate 3g was prepared according to the method of Korch.4 Tris(4,4’-
methoxydibenzylideneacetone)dipalladium(0) [Pd2(pmdba)3] was prepared according to 
the method of Ibers5 or Fairlamb.6 AgOPiv was prepared using Grubbs’ procedure.7 tert-
Butyl ((phenylsulfonyl)methyl)carbamate and benzyl ((phenylsulfonyl)methyl)carbamate 
were prepared according to the method of Zwierzak or Dikshit.8 Benzyl 3-oxopiperazine-
1-carboxylate was prepared according to the method of Batey.9 2-chloroallyl chloroformate 
was prepared according to the method of Stoltz.10  
 
Experimental Procedures for the Synthesis of Piperazinone Allylic Alkylation 
Substrates 
 
 
 
tert-butyl 4-benzoyl-3-oxopiperazine-1-carboxylate (SI-1). To a solution of tert-butyl 
3-oxopiperazine-1-carboxylate 1 (5.0 g, 24.9 mmol, 1 equiv) in THF (250 mL) at −78 °C 
was added dropwise nBuLi (11.4 mL, 2.4M solution in hexane, 27.5 mmol, 1.1 equiv) over 
20 minutes. The resulting yellow solution was stirred for 10 min at −78 °C. Benzoyl 
chloride (3.48 mL, 30.0 mmol, 1.2 equiv) was then added dropwise at −78 °C, giving an 
orange solution. The reaction was stirred for 2.5 h at −78 °C, quenched by addition of 
saturated aqueous NH4Cl (100 mL), and diluted with ethyl acetate (100 mL). The layers 
were separated and the aqueous layer was extracted with ethyl acetate (3 × 100 mL). The 
combined organic layers were dried over anhydrous Na2SO4, decanted, and concentrated 
under reduced pressure onto silica gel. The silica-loaded crude reaction mixture was 
purified by silica gel flash column chromatography (10% →15% →20% EtOAc/hexanes) 
to give protected ketopiperazine SI-1 as a white solid (3.2 g, 42.1% yield). Product identity 
was confirmed by comparison to previously reported characterization data.11 
 
 
 
 
tert-butyl 4-(4-methoxybenzoyl)-3-oxopiperazine-1-carboxylate (SI-2). To a solution 
of tert-Butyl 3-oxopiperazine-1-carboxylate (5.0 g, 24.9 mmol, 1 equiv) in THF (250 mL) 
at −78 °C was added dropwise nBuLi (11.4 mL, 2.4M solution in hexane, 27.5 mmol, 1.1 
equiv) over 20 minutes. The resulting yellow solution was stirred for 10 min at −78 °C. 
Anisoyl chloride (4.1 mL, 30.0 mmol, 1.2 equiv) was then added dropwise at −78 °C, 
giving a bright orange solution. The reaction was stirred for 2 h at −78 °C, quenched by 
addition of saturated aqueous NH4Cl (100 mL), and diluted with ethyl acetate (100 mL). 
The layers were separated and the aqueous layer was extracted with ethyl acetate (3 × 100 
mL). The combined organic layers were dried over anhydrous Na2SO4, decanted, and 
BzN
NBoc
O
NBoc
O
N
O
MeO
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concentrated under reduced pressure onto silica gel. The silica-loaded crude reaction 
mixture was filtered through a plug of silica (1% →2% MeOH/CH2Cl2) to give crude 
anisoyl protected ketopiperazine SI-2 as a white foam, which was directly used without 
further purification in subsequent acylation reactions with allyl cyanoformate.  
 
 
benzyl 4-benzoyl-3-oxopiperazine-1-carboxylate (SI-3). To a solution of benzyl 3-
oxopiperazine-1-carboxylate9 (1.0 g, 4.3 mmol, 1.0 equiv) in THF (42 mL) at −78 °C was 
added dropwise nBuLi (1.96 mL, 2.4M solution in hexane, 4.7 mmol, 1.1 equiv) over 20 
minutes. The solution was stirred for 10 min at −78 °C. Benzoyl chloride (0.595 mL, 5.1 
mmol, 1.2 equiv) was then added dropwise at −78 °C, giving a light yellow solution. The 
reaction was stirred for 1 h at −78 °C, quenched by addition of saturated aqueous NH4Cl 
(50 mL), and diluted with ethyl acetate (50 mL). The layers were separated and the aqueous 
layer was extracted with ethyl acetate (3 × 50 mL). The combined organic layers were dried 
over anhydrous Na2SO4, decanted, and concentrated under reduced pressure onto silica gel. 
The silica-loaded crude reaction mixture was purified by silica gel flash column 
chromatography (33% EtOAc/hexanes) to give Bz-Cbz-protected ketopiperazine SI-3 as a 
white solid (1.0 g, 70.0% yield); 1H NMR (500 MHz, CDCl3) δ 7.61 – 7.56 (m, 2H), 7.54 
– 7.49 (m, 1H), 7.44 – 7.31 (m, 7H), 5.21 (s, 2H), 4.30 (s, 2H), 3.95 (dd, J = 6.8, 4.4 Hz, 
2H), 3.83 (dd, J = 6.9, 4.3 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ (a mixture of two 
rotamers) 172.8, 168.0, 167.6, 154.5, 136.0, 135.0, 132.3, 128.7, 128.5, 128.4, 128.3, 
128.3, 68.0, 48.5, 43.3, 41.7, 41.4; IR (Neat Film, NaCl) 3386, 3063, 3033, 2954, 2894, 
1706, 1600, 1584, 1498, 1449, 1422, 1394, 1367, 1302, 1231, 1177, 1162, 1123, 1060, 
1028, 1010, 944, 857, 796, 765, 731, 699, 639, 612 cm-1; HRMS (MM: ESI-APCI) m/z 
calc’d for C19H19N2O4 [M+H]+: 339.1339, found 339.1338. 
 
 
 
 
2-allyl 1-(tert-butyl) 4-benzoyl-3-oxopiperazine-1,2-dicarboxylate (2). To a solution 
of Bz-protected oxopiperazine SI-1 (1.5 g, 4.9 mmol, 1.0 equiv) in THF (40 mL) at −78 °C 
was added LiHMDS (907 mg, 5.42 mmol, 1.10 equiv.) in THF (10mL) dropwise. The 
resulting orange reaction mixture was stirred for 15 min at −78 °C. Then, allyl 
cyanoformate (590 µL, 5.2 mmol, 1.05 equiv) was added dropwise at −78 °C, giving a 
yellow solution. After stirring for 1.5 h at −78 °C, the reaction was quenched with saturated 
aqueous NH4Cl (20 mL) and diluted with ethyl acetate (50 mL). The aqueous phase was 
extracted with ethyl acetate (3 x 100 mL). The combined organic layers were dried over 
anhydrous Na2SO4, decanted, and concentrated under reduced pressure onto silica. The 
silica-loaded crude mixture was purified by silica gel flash chromatography (10% → 20% 
EtOAc/hexanes) to give the allyl ester 2 as a white solid (1.3 g, 68% yield): 1H NMR (500 
MHz, CDCl3) δ (a mixture of two rotamers) 7.59 (d, J = 7.7 Hz, 2H), 7.52 (t, J = 7.6 Hz, 
1H), 7.40 (t, J = 7.6 Hz, 2H), 5.92 (m, 1H), 5.44 – 5.07 (m, 3H), 4.84 – 4.57 (m, 2H), 4.28 
BzN
NCbz
O
NBoc
O
O
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– 3.61 (m, 4H), 1.43 (br s, 9H); 13C NMR (126 MHz, CDCl3) δ (a mixture of two rotamers) 
172.7, 166.9, 164.4, 154.1, 153.5, 134.6, 132.6, 131.0, 128.6, 128.4, 119.9, 119.4, 82.2, 
82.0, z67.1, 62.7, 61.7, 43.2, 42.6, 41.5, 40.2, 29.4, 28.3; IR (Neat Film, NaCl) 2978 1746 
1695 1600 1450 1393 1367 1310 1277 1231 1177 1158 1127 1088 1059 1009 958 861 794 
770 728 694 623 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C16H17N2O6 [(M-
tBu)+H]+: 333.1081, found 333.1075. 
 
 
  
 
2-allyl 1-(tert-butyl) 4-(4-methoxybenzoyl)-3-oxopiperazine-1,2-dicarboxylate (3b). 
Following the procedure described for the preparation of 2, anisoyl protected 
oxopiperazine SI-2 (1.0 g, 3.0 mmol, 1.0 equiv) was treated with LiHMDS (550 mg, 3.3 
mmol, 1.1 equiv) and acylated with allyl cyanoformate (336 µL, 3.1 mmol, 1.05 equiv) to 
give, after purification by silica gel flash chromatography (Dry load SiO2, 18% 
EtOAc/hexanes), allyl ester 3b as a white solid (566 mg, 45% yield): 1H NMR (400 MHz, 
CDCl3) δ (a mixture of two rotamers) 7.61 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 
5.91 (ddt, J = 16.4, 10.8, 5.8 Hz, 1H), 5.46–5.12 (m, 3H), 4.70 (s, 2H), 4.13–3.65 (m, 4H),  
3.81 (s, 3H), 1.46 (m, 9H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 
171.9, 171.8, 167.0, 164.4, 164.2, 163.4, 154.0, 153.4, 131.4, 131.0, 126.3, 119.6, 119.2, 
113.6, 82.0, 81.8, 66.9, 62.5, 61.6, 55.5, 43.3, 42.8, 41.5, 40.1, 28.2; IR (Neat Film, NaCl) 
3384, 3060, 2978, 2843, 2568, 2049, 1732, 1605, 1580, 1513, 1456, 1372, 1258, 1088, 
1059, 959, 844, 769, 736, 706, 634 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for 
C21H27N2O7 [M+H]+: 419.1813, found 419.1815. 
 
 
  
 
2-allyl 1-benzyl 4-benzoyl-3-oxopiperazine-1,2-dicarboxylate (3c). Following the 
procedure described for the preparation of 2, Cbz protected oxopiperazine SI-3 (1.0 g, 3.0 
mmol, 1.0 equiv) was treated with LiHMDS (544 mg, 3.3 mmol, 1.1 equiv) and acylated 
with allyl cyanoformate (331 µL, 3.1 mmol, 1.05 equiv) to give, after purification by silica 
gel flash chromatography (dry load SiO2, 20 → 25% EtOAc/hexanes), allyl ester 3a as a 
white solid (720 mg, 58% yield): 1H NMR (500 MHz, CDCl3) δ (a mixture of two 
rotamers) 7.65 – 7.56 (m, 2H), 7.56 – 7.46 (m, 1H), 7.46 – 7.28 (m, 7H), 5.87 (dtd, J = 
47.5, 10.7, 5.4 Hz, 1H), 5.55 – 5.04 (m, 5H), 4.84 – 4.48 (m, 2H), 4.24 – 3.99 (m, 2H), 
3.99 – 3.66 (m, 2H); 13C NMR (126 MHz, CDCl3) δ (a mixture of two rotamers) 172.4, 
172.3, 166.5, 164.0, 163.8, 154.8, 154.2, 135.7, 135.6, 134.4, 132.5, 130.9, 130.8, 128.7, 
128.6, 128.5, 128.5, 128.4, 128.3, 128.2, 128.1, 119.6, 119.5, 68.3, 68.2, 67.2, 67.1, 62.1, 
61.9, 42.8, 42.3, 41.3, 40.8; IR (Neat Film, NaCl) 3386, 3064, 3033, 2955, 2897, 1746, 
1713, 1694, 1651, 1600, 1584, 1498, 1450,  1417, 1368, 1304, 1278, 1229, 1195, 1178, 
NBoc
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1160, 1124, 1088, 1061, 1014, 985, 951, 860, 794, 768, 729, 696, 675, 623 cm-1; HRMS 
(MM: ESI-APCI) m/z calc’d for C23H23N2O6 [M+H]+: 423.1551, found 423.1547. 
 
 
  
 
1-(tert-butyl) 2-(2-chloroallyl) 4-benzoyl-3-oxopiperazine-1,2-dicarboxylate (3d). 
Following the procedure described for the preparation of 2, benzoyl protected 
oxopiperazine SI-1 (440 mg, 1.5 mmol, 1.0 equiv) was treated with LiHMDS (267 mg, 1.6 
mmol, 1.1 equiv) and acylated with 2-chloroallyl chloroformate10 (235 mg, 1.5 mmol, 1.05 
equiv) to give, after purification by silica gel flash chromatography (Dry load SiO2, 15% 
EtOAc/hexanes), 2-chloroallyl ester 3d as an off-white solid (431 mg, 70% yield): 1H 
NMR (500 MHz, CDCl3): δ (a mixture of two rotamers) 7.59–7.54 (m, 2H), 7.50–7.44 
(m, 1H), 7.43–7.37 (m, 2H), 6.67 (m, 1H), 5.42–5.33 (m, 2H), 4.54 (m, 2H), 3.95–3.89 (m, 
2H), 3.72 (t, J = 5.2 Hz, 2H), 1.51 (s, 9H); 13C NMR (101 MHz, CDCl3): δ (a mixture of 
two rotamers) 167.5, 167.3, 152.4, 152.2, 151.1, 151.0, 135.1, 134.9, 134.3, 131.3, 131.2, 
128.5, 128.4, 128.0, 127.9, 126.7, 115.9, 115.7, 107.9, 107.6, 82.3, 82.2, 69.9, 69.8, 44.2, 
43.1, 42.3, 41.7, 28.3; IR (Neat Film, NaCl) 3396, 3129, 3062, 2979, 2936, 2253, 1770, 
1691, 1372, 1242, 1050, 987, 950, 922, 859, 839, 764, 731, 707, 647 cm-1; HRMS (MM: 
ESI-APCI) m/z calculated for C20H24ClN2O6 [M+H]+: 423.1317, found 423.1316. 
 
 
  
 
2-allyl 1-(tert-butyl) 4-(4-methoxybenzoyl)-2-methyl-3-oxopiperazine-1,2-
dicarboxylate (3e). Sodium hydride (60% in mineral oil, 25 mg, 0.62 mmol, 1.2 equiv) 
was added to a solution of allyl ester 2 (200 mg, 0.52 mmol, 1.0 equiv) in THF (5 mL) at 
0 °C. After stirring for 30 min at 0 °C, MeI (160 µL, 2.57 mmol, 5.0 equiv) was added. The 
reaction mixture was allowed to warm to room temperature and stirred for 16 h. The 
reaction was quenched with aqueous NH4Cl (10 mL) and extracted with EtOAc (3 x 5 mL). 
The combined organic phases were dried over anhydrous Na2SO4, decanted, and 
concentrated under reduced pressure onto silica gel. The silica-loaded residue was purified 
by silica gel flash chromatography (20% EtOAc/hexanes) to give methylated allyl ester 3e 
as a colorless oil (180 mg, 85% yield): 1H NMR (400 MHz, CDCl3): δ 7.59 – 7.46 (m, 
3H), 7.46 – 7.32 (m, 2H), 5.92 (ddt, J = 17.2, 10.4, 5.8 Hz, 1H), 5.41 – 5.19 (m, 2H), 4.66 
(d, J = 5.8 Hz, 2H), 4.24 – 4.09 (m, 1H), 4.05 – 3.90 (m, 2H), 3.81 – 3.64 (m, 1H), 1.84 (s, 
3H), 1.46 (s, 9H); 13C NMR (101 MHz, CDCl3): δ (a mixture of two rotamers) 172.5, 
169.2, 168.0, 153.2, 134.8, 132.4, 131.5, 128.4, 128.0, 119.1, 82.7, 68.7, 66.9, 43.7, 40.9, 
28.3, 21.5; IR (Neat Film, NaCl) 3384, 3064, 2980, 2939, 2876, 1962, 1766, 1694, 1600, 
1584, 1451, 1394, 1368, 1306, 1270, 1232, 1206, 1164, 1096, 1060, 1032, 1016, 993, 968, 
936, 854, 795, 770, 727, 696, 675, 633, 618 cm-1; HRMS (MM: ESI-APCI) m/z calculated 
for C16H19N2O4 [(M-Boc)+H]+: 303.1341, found 303.1339. 
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2-allyl 1-(tert-butyl) 4-(4-methoxybenzoyl)-2-methyl-3-oxopiperazine-1,2-
dicarboxylate (3f). Following the procedure described for the preparation of 3e, anisoyl 
protected oxopiperazine 3b (120 mg, 0.29 mmol, 1.0 equiv) was treated with NaH (60% in 
mineral oil, 13 mg, 0.32 mmol, 1.1 equiv) and methylated with MeI (90 µL, 1.43 mmol, 
5.0 equiv) to give, after purification by silica gel flash chromatography (dry load SiO2, 
15% → 20% → 25% → 30% EtOAc/hexanes), methylated allyl ester 3f as a colorless oil 
(110 mg, 89% yield): 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 8.8 Hz, 2H), 6.85 (d, J 
= 8.9 Hz, 2H), 5.92 (ddt, J = 17.2, 10.4, 5.8 Hz, 1H), 5.40 – 5.17 (m, 2H), 4.66 (d, J = 5.8 
Hz, 2H), 4.15 – 4.02 (m, 1H), 4.02 – 3.87 (m, 2H), 3.83 (s, 3H), 3.80 – 3.67 (m, 1H), 1.84 
(s, 3H), 1.46 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 171.8, 169.0, 168.1, 163.4, 153.2, 
131.5, 131.0, 126.6, 119.0, 113.7, 82.6, 68.5, 66.8, 55.5, 43.8, 41.0, 28.3, 21.6; IR (Neat 
Film, NaCl) 3081, 2978, 2938, 2842, 1766, 1702, 1604, 1579, 1512, 1460, 1394, 1368, 
1308, 1287, 1259, 1235, 1208, 1169, 1114, 1095, 1060, 1021, 1004, 969,  933, 845, 789, 
770, 733, 706, 648, 634 cm-1; HRMS (MM: ESI-APCI) m/z calculated for C18H21N2O7 
[(M-tBu)+H]+: 377.1343, found 377.1339. 
 
 
  
 
2-allyl 1-(tert-butyl) 2-benzyl-4-(4-methoxybenzoyl)-3-oxopiperazine-1,2-
dicarboxylate (3h). Following the procedure described for the preparation of 3e, anisoyl-
protected allyl ester 3b (200 mg, 0.48 mmol, 1.0 equiv) was treated with potassium hydride 
(23 mg, 0.57 mmol, 1.2 equiv) and alkylated with benzyl bromide (170 µL, 1.43 mmol, 3.0 
equiv) to give, after purification by silica gel flash chromatography (Dry load SiO2, 20% 
→ 25% EtOAc/hexanes), the benzyl ester 3h as a colorless oil (100 mg, 41% yield) (Note: 
attempts using sodium hydride as a base failed to give conversion of starting material. 
Instead, potassium hydride resulted in conversion to the desired product.):  1H NMR (400 
MHz, CDCl3) δ (a mixture of two rotamers) 7.52 (m, 2H), 7.42 – 7.23 (m, 3H), 7.11 (m, 
2H), 6.92 – 6.75 (m, 2H), 5.97 (ddt, J = 17.2, 10.4, 5.8 Hz, 1H), 5.50 – 5.17 (m, 2H), 4.87 
– 4.57 (m, 2H), 3.86 (s, 3H), 3.79 – 3.56 (m, 4H), 2.95 (ddd, J = 13.3, 7.4, 3.0 Hz, 1H), 
2.86 (br s, 1H), 1.55 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 
172.1, 168.0, 167.4, 166.9, 163.4, 153.6, 153.4, 136.0, 135.3, 131.8, 131.3, 130.7, 128.8, 
128.7, 128.4, 128.2, 127.8, 127.7, 127.5, 126.6, 119.4, 118.9, 113.7, 82.9, 81.8, 72.7, 67.0, 
66.5, 55.6, 44.5, 43.0, 42.2, 41.4, 40.8, 40.0, 38.8, 28.5; IR (Neat Film, NaCl) 2978, 1764, 
1698, 1604, 1512, 1496, 1455, 1394, 1366, 1307, 1282, 1256, 1196, 1155, 1078, 1020, 
1000, 921, 844, 768 733, 704 cm-1; HRMS (MM: ESI-APCI) m/z calculated for 
C28H33N2O7 [M+H]+: 509.2282, found 509.2285. 
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2-allyl 1-(tert-butyl) 4-benzoyl-2-((benzyloxy)methyl)-3-oxopiperazine-1,2-
dicarboxylate (3i). Following the procedure described for the preparation of 3e, allyl ester 
2 (150 mg, 0.39 mmol, 1.00 equiv) was treated with sodium hydride (17 mg, 0.42 mmol, 
1.1 equiv) and alkylated with benzyl chloromethyl ether (107 µL, 0.77 mmol, 2.0 equiv) to 
give, after purification by silica gel flash chromatography (Dry load SiO2, 10% → 15% 
EtOAc/hexanes), benzyloxy methyl ether 3i as a colorless oil (50 mg, 55% yield BRSM): 
1H NMR (500 MHz, CDCl3) δ (a mixture of two rotamers) 7.64 – 7.55 (m, 2H), 7.51 – 
7.44 (m, 1H), 7.41 – 7.27 (m, 7H), 5.88 (ddt, J = 17.3, 10.4, 5.8 Hz, 1H), 5.40 – 5.17 (m, 
2H), 4.74 – 4.47 (m, 4H), 4.38 (m, 1H), 4.17 (m, 1H), 4.08 – 3.84 (m, 4H), 1.42 (m, 9H); 
13C NMR (126 MHz, CDCl3) δ (a mixture of two rotamers) 173.0, 167.4, 167.2, 166.5, 
153.6, 153.1, 141.0, 137.9, 137.5, 134.8, 132.4, 131.6, 131.1, 128.7, 128.7, 128.6, 128.4, 
128.3, 128.0, 127.7, 127.6, 127.1, 119.5, 118.9, 82.7, 81.9, 73.9, 73.3, 72.6, 71.2, 71.1, 
66.8, 65.4, 43.6, 43.4, 42.5, 41.7, 28.4, 28.3; IR (Neat Film, NaCl) 3528, 3064, 3031, 
2978, 2934, 1762, 1694, 1600, 1496, 1453, 1394, 1366, 1314, 1270, 1231, 1205, 1161, 
1094, 1055, 1014, 972, 941, 854, 795, 770, 730, 696, 674, 624 cm-1; HRMS (MM: ESI-
APCI) m/z calculated for C24H25N2O7 [(M-tBu)+H]+: 453.1656, found 453.1649. 
 
 
 
 
2-allyl 1-(tert-butyl) 2-(2-cyanoethyl)-4-(4-methoxybenzoyl)-3-oxopiperazine-1,2-
dicarboxylate (3j). DBU (7.1 µL, 0.048 mmol, 0.10 equiv) was added to a solution of allyl 
ester 3b (200 mg, 0.478 mmol, 1.0 equiv) and acrylonitrile (94 µL, 1.43 mmol, 3.0 equiv) 
in DMF (2.4 mL) at room temperature. After stirring for 2 h at 70 °C and 24 h at 55 °C, 
additional DBU (14 µL, 0.1 mmol, 0.2 equiv) was added and the orange solution was 
maintained at 70 °C for 4 h. Then, additional DBU (21 µL, 0.143 mmol, 0.30 equiv) was 
added and the mixture was stirred at 70 °C for 3 h. After allowing the reaction mixture to 
cool to room temperature, the reaction was quenched with saturated aqueous NH4Cl (2 mL) 
and diluted with EtOAc (6 mL). The aqueous phase was extracted with EtOAc (3 x 5 mL). 
The combined organic layers were dried over anhydrous Na2SO4, decanted, and 
concentrated under reduced pressure onto silica gel. The silica-loaded residue was purified 
by flash chromatography (20% EtOAc/hexanes) to give the α-cyanoethylated allyl ester 3j 
as a pale yellow oil (77.6 mg, 34% yield): 1H NMR (400 MHz, CDCl3) δ 7.54 (s, 2H), 
6.85 (d, J = 8.9 Hz, 2H), 5.92 (ddt, J = 17.2, 10.4 Hz, 5.9 Hz, 1H), 5.36 (dd, J = 17.2, 1.4 
Hz, 1H), 5.29 (d, J = 10.5 Hz, 1H), 4.69 (d, J = 5.8 Hz, 2H), 4.25 (s, 1H), 4.06 (ddd, J = 
13.1, 5.7, 3.1 Hz, 1H), 3.96 (ddd, J = 13.1, 8.6, 3.4 Hz, 1H), 3.83 (s, 3H), 3.64 – 3.49 (m, 
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1H), 2.77 (s, 2H), 2.49 (m, 1H), 2.44 – 2.31 (m, 1H), 1.47 (s, 9H); 13C NMR (101 MHz, 
CDCl3) δ 171.7, 167.24, 166.3, 163.5, 153.4, 131.1, 126.2, 119.6, 119.1, 113.8, 82.9, 70.5, 
67.3, 55.5, 43.9, 42.3, 29.8, 28.2, 12.8; IR (Neat Film, NaCl) 2978, 2249, 1760, 1694, 
1604, 1579, 1512, 1462, 1394, 1368, 1311, 1258, 1160, 1018, 933, 846, 769, 737, 704 cm-
1; HRMS (MM: ESI-APCI): m/z calc’d for C24H30N3O7 [M+H]+: 472.2078, found 
472.2078.  
 
 
  
 
2-allyl 1-(tert-butyl) 4-(4-methoxybenzoyl)-3-oxo-2-(3-oxobutyl)piperazine-1,2-
dicarboxylate (3k). To a solution of allyl ester 3b (200 mg, 0.5 mmol, 1.0 equiv) and 
methyl vinyl ketone (80 µL, 0.96 mmol, 2.0 equiv) in acetone (2 mL) at room temperature 
was added DBU (7.1 µL, 0.05 mmol, 0.1 equiv). After stirring for 24 h at 55 °C, additional 
DBU (7.1 µL, 0.05 mmol, 0.1 equiv) was added and the orange solution was maintained at 
55 °C for an additional 24 h. The reaction mixture was allowed to cool to ambient 
temperature and concentrated under reduced pressure onto silica gel. The silica-loaded 
crude reaction mixture was purified by silica gel flash column chromatography (33% 
EtOAc/hexanes) to afford the ketone 3k as a pale yellow oil (90 mg, 39% yield): 1H NMR 
(400 MHz, CDCl3) δ 7.56 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 8.9 Hz, 2H), 5.92 (ddt, J = 17.2, 
10.4, 5.8 Hz, 1H), 5.35 (dd, J = 17.2, 1.5 Hz, 1H), 5.26 (d, J = 10.4 Hz, 1H), 4.71 – 4.60 
(m, 2H), 4.11 – 3.93 (m, 3H), 3.82 (s, 3H), 3.71 – 3.59 (m, 1H), 2.72 (q, J = 9.3, 8.1 Hz, 
1H), 2.60 (dt, J = 9.6, 6.2 Hz, 3H), 2.10 (s, 3H), 1.45 (s, 9H); 13C NMR (101 MHz, CDCl3) 
δ 207.8, 172.0, 167.9, 167.4, 163.4, 153.5, 131.5, 131.1, 126.6, 119.2, 113.7, 82.4, 70.6, 
66.9, 55.5, 43.5, 42.1, 38.8, 29.8, 28.7, 28.3; IR (Neat Film, NaCl): 2977, 2934, 1761, 
1704, 1604, 1512, 1456, 1394, 1367, 1312, 1257, 1199, 1168, 1090, 1018, 845, 768 cm-1; 
HRMS (MM: ESI-APCI): m/z calc’d for C25H33N2O8 [M+H]+: 489.2231, found: 
489.2228. 
 
 
  
 
2-allyl 1-(tert-butyl) 2-((((benzyloxy)carbonyl)amino)methyl)-4-(4-methoxybenzoyl)-
3-oxopiperazine-1,2-dicarboxylate (3l). Following the procedure described for the 
preparation of 3m, anisoyl-protected allyl ester 3b (400 mg, 0.96 mmol, 1.0 equiv) was 
treated with Cs2CO3 (779 mg, 02.39 mmol, 2.5 equiv) and alkylated with benzyl 
((phenylsulfonyl)methyl)carbamate8 (350 mg, 1.15 mmol, 2.5 equiv) to give, after 
purification by silica gel flash chromatography (Dry load SiO2, 10% → 15% → 20% 
EtOAc/hexanes), the aminomethyl allyl ester 3l as a white foam (300 mg, 54% yield): 1H 
NMR (400 MHz, CDCl3) δ (a mixture of two rotamers) 7.69 – 7.50 (m, 2H), 7.41 – 7.25 
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(m, 5H), 6.95 – 6.72 (m, 2H), 5.92 (ddt, J = 17.3, 10.4, 5.9 Hz, 1H), 5.49 – 4.96 (m, 5H), 
4.85 – 4.53 (m, 2H), 4.27 – 3.87 (m, 5H), 3.83 (d, J = 14.6 Hz, 3H), 3.60 (d, J = 22.7 Hz, 
1H), 1.47 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 171.7, 
167.3, 166.5, 163.4, 156.8, 153.7, 152.7, 136.4, 134.21, 132.5, 131.5, 131.2, 129.4, 129.3, 
128.9, 128.6, 128.3, 126.5, 119.8, 119.3, 113.7, 83.1, 82.1, 71.4, 70.6, 68.3, 67.8, 67.0, 
55.5, 45.0, 44.2, 43.7, 42.9, 41.9, 28.3; IR (Neat Film, NaCl) 3366, 2977, 1704, 1604, 
1513, 1456, 1394, 1367, 1313, 1257, 1232, 1169, 1091, 1018, 1002, 845, 767, 698 cm-1; 
HRMS (MM: ESI-APCI): m/z calc’d for C30H36N3O9 [M+H]+: 582.2446, found 
582.2438. 
 
 
 
 
2-allyl 1-(tert-butyl) 4-benzoyl-2-(((tert-butoxycarbonyl)amino)methyl)-3-  
oxopiperazine-1,2-dicarboxylate (3m). To a suspension of allyl ester 2 (200 mg, 0.5 
mmol, 1.0 equiv) and tert-butyl ((phenylsulfonyl)methyl)carbamate8 (168 mg, 0.6 mmol, 
1.2 equiv), in dichloromethane (2.5 mL) at room temperature was added Cs2CO3 (419 mg, 
1.3 mmol, 2.5 equiv). After stirring for 3 h, saturated aqueous NH4Cl (1 mL) was added 
and the biphasic mixture was vigorously stirred for 20 min. The aqueous phase was 
extracted with dichloromethane (3 x 3 mL). The combined organic phases were dried over 
anhydrous Na2SO4, decanted, and concentrated under reduced pressure onto silica gel. The 
silica-loaded crude reaction mixture was purified by silica gel flash column 
chromatography (15% EtOAc/hexanes) to give methylcarbamate allyl ester 3m as a white 
foam (202 mg, 76% yield): 1H NMR (400 MHz, CDCl3) δ (a mixture of two rotamers) 
7.55 (d, J = 7.5 Hz, 2H), 7.49 (t, J = 7.5 Hz, 1H), 7.36 (t, J = 7.7 Hz, 2H), 5.91 (ddt, J = 
16.5, 10.4, 5.8 Hz, 1H), 5.34 – 5.27 (m, 2H), 4.96 (m, 1H), 4.66 (br s, 2H), 4.19 – 3.85 (m, 
5H), 3.79 – 3.64 (m, 1H), 1.48 (s, 9H), 1.40 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (a 
mixture of two rotamers) 172.4, 167.3, 166.8, 156.1, 153.6, 152.9, 134.9, 132.4, 131.7, 
131.1, 128.3, 128.3, 119.6, 119.0, 83.1, 82.1, 79.9, 71.4, 70.6, 67.0, 44.3, 43.8, 43.2, 42.2, 
41.6, 28.4, 28.3; IR (Neat Film, NaCl) 3386, 2978, 1760, 1698, 1601, 1505, 1451, 1394, 
1367, 1314, 1232, 1203, 1164, 1092, 1067, 1012, 915, 854, 766, 730, 696 cm-1; HRMS 
(MM: ESI-APCI): m/z calc’d for C26H36N3O8 [M+H]+: 518.2497, found 518.2496.  
 
 
Experimental Procedures for the Synthesis of Tetrahydropyrimidinone Allylic 
Alkylation Substrates 
 
  
 
tert-Butyl 4-oxotetrahydropyrimidine-1(2H)-carboxylate (SI-4). A solution of 3-
aminopropanamide hydrochloride (5 g, 40.1 mmol, 1.0 equiv), potassium hydroxide (3.38 
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g, 60.2 mmol, 1.5 equiv), and formaldehyde (37% in water, 5.97 mL, 80.3 mmol, 2.0 equiv) 
in ethanol (13 mL) was stirred at reflux for 4 h. The suspension was then maintained at 
55 °C while triethylamine (5.5 mL, 40.1 mmol, 1 equiv) and di-tert-butyl dicarbonate (9.2 
g, 42.1 mmol, 1.05 equiv) were added successively. The reaction was stirred for 2 h at 
55 °C and then allowed to cool to ambient temperature. The precipitate was filtered off, 
the filtrate was concentrated under reduced pressure, and was then purified by silica gel 
flash chromatography (1 → 3% MeOH/CH2Cl2) to afford Boc-protected 
tetrahydropyrimidinone SI-4 as a white solid (4.09 g, 51% yield over two steps): 1H NMR 
(500 MHz, CDCl3) δ 8.14 – 7.60 (m, 1H), 4.77 – 4.61 (m, 2H), 3.58 (t, J = 6.5 Hz, 2H), 
2.41 (t, J = 6.5 Hz, 2H), 1.41 (s, 9H); 13C NMR (126 MHz, CDCl3) δ (a mixture of two 
rotamers) 171.5, 153.8, 153.4, 81.1, 54.8, 54.0, 40.4, 39.4, 31.4, 28.3; IR (Neat Film, 
NaCl) 3193, 2970, 1710, 1643, 1488, 1404, 1366, 1326, 1276, 1245, 1210, 1159, 1136, 
1020, 949, 776 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C9H17N2O3 [M+H]+: 
201.1234, found 201.1231. 
 
 
  
 
tert-Butyl 3-benzoyl-4-oxotetrahydropyrimidine-1(2H)-carboxylate (SI-5). To a 
solution of tetrahydropyrimidinone SI-4 (2.07 g, 10.4 mmol, 1.0 equiv) in THF (100 mL) 
at −78 °C was added n-butyllithium (2.2 M in hexanes, 4.94 mL, 10.9 mmol, 1.05 equiv) 
dropwise over 10 min. After stirring the solution at −78 °C for 20 min, benzoyl chloride 
(1.43 mL, 12.4 mmol, 1.2 equiv) was added dropwise at −78 °C. The reaction solution was 
stirred at −78 °C for 40 min, allowed to warm up to room temperature, and was then 
quenched with saturated aqueous NH4Cl (50 mL). The mixture was diluted with EtOAc 
(100 mL) and the aqueous phase was extracted with EtOAc (3 x 80 mL). The combined 
organic phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced 
pressure onto silica gel. The silica-loaded residue was purified by silica gel flash 
chromatography (30% EtOAc/hexanes) to give Bz-protected tetrahydropyrimidinone SI-5 
as a white solid (2.72 g, 86% yield): 1H NMR (400 MHz, Chloroform-d) δ 7.55 (dt, J = 
8.3, 1.4 Hz, 2H), 7.50 (t, J = 7.4 Hz, 1H), 7.39 (t, J = 7.6 Hz, 2H), 5.28 (s, 2H), 3.74 (t, J 
= 6.6 Hz, 2H), 2.68 (t, J = 6.6 Hz, 2H), 1.49 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 172.3, 
170.7, 153.8, 135.0, 132.2, 128.4, 128.2, 81.7, 57.0, 40.4, 33.4, 28.3; IR (Neat Film, NaCl) 
2978, 1698, 1480, 1450, 1408, 1367, 1304, 1266, 1239, 1141, 1015, 936, 863, 797, 700, 
618 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C16H21N2O4 [M+H]+: 305.1496, 
found 305.1500. 
 
 
  
 
5-Allyl 1-(tert-butyl) 3-benzoyl-4-oxotetrahydropyrimidine-1,5(2H)-dicarboxylate 
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(SI-6). To a solution of diisopropylamine (224 µL, 1.59 mmol, 1.2 equiv) in THF (3 mL) 
at −78 °C was added n-butyllithium (2.2 M in hexanes, 664 µL, 1.46 mmol, 1.1 equiv). 
The solution was maintained at −78 °C for 15 min and then cannulated over 10 min into a 
solution of Bz-protected tetrahydropyrimidine SI-5 (404 mg, 1.33 mmol, 1.0 equiv) in THF 
(10 mL) at −78 °C. After stirring the solution at −78 °C for 25 min, allyl cyanoformate 
(156 µL, 1.46 mmol, 1.1 equiv) was added dropwise at −78 °C. The reaction mixture was 
maintained at −78 °C for 50 min and was then quenched with saturated aqueous NH4Cl (10 
mL). The reaction mixture was diluted with EtOAc (10mL) and allowed to warm to room 
temperature. The aqueous phase was extracted with EtOAc (3 x 15 mL) and the combined 
organic phases were dried over anhydrous Na2SO4, decanted, and concentrated 
under reduced pressure onto silica gel. The silica-loaded residue was purified by silica gel 
flash chromatography (18 → 20 → 30% EtOAc/hexanes) to give re-isolated starting 
material SI-5 (154 mg, 38% yield) and allyl ester SI-6 as a white crystalline solid (310 mg, 
60% yield, 97% yield based on recovered starting material):  1H NMR (400 MHz, CDCl3) 
δ 7.70 (d, J = 7.2 Hz, 2H), 7.51 (t, J = 7.4 Hz, 1H), 7.40 (t, J = 7.6 Hz, 2H), 5.95 (ddt, J = 
17.2, 10.4, 5.9 Hz, 1H), 5.37 (dq, J = 17.2, 1.5 Hz, 1H), 5.36 (m, 1H), 5.30 (dd, J = 10.4, 
1.3 Hz, 1H), 5.17 (d, J = 12.6 Hz, 1H), 4.69 (d, J = 6.0 Hz, 2H), 4.27 (ddd, J = 13.7, 5.4, 
1.2 Hz, 1H), 3.85 (dd, J = 13.7, 6.2 Hz, 1H), 3.63 (t, J = 5.7 Hz, 1H), 1.49 (s, 9H); 13C 
NMR (101 MHz, CDCl3) δ 172.9, 167.8, 167.0, 153.4, 134.6, 132.5, 131.3, 128.7, 128.3, 
119.7, 82.3, 67.0, 58.5, 50.1, 43.9, 28.3; IR (Neat Film, NaCl) 3406, 3064, 2978, 2935, 
1714, 1601, 1480, 1450, 1416, 1369, 1287, 1148, 1072, 1017, 934 , 859, 796, 768, 736, 
703, 626 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C20H25N2O6 [M+H]+: 389.1707, 
found 389.1708. 
 
 
  
 
1-(tert-butyl) 3-benzoyl-5-methyl-4-oxotetrahydropyrimidine-1,5(2H)-dicarboxylate 
(5a). To a solution of allyl ester SI-6 (100 mg, 0.26 mmol, 1.0 equiv) in acetonitrile (2.6 
mL) at 0 °C was added cesium carbonate (168 mg, 0.52 mmol, 2.0 equiv). After stirring 
the suspension for 30 min at 0 °C, methyl iodide (48 µL, 0.77 mmol, 3.0 equiv) was added. 
The reaction mixture was stirred for 3 h at 0 °C and diluted with saturated aqueous NH4Cl 
(2 mL) and EtOAc (2 mL). The aqueous phase was extracted with EtOAc (4 x 3 mL) and 
the combined organic phases were dried over anhydrous Na2SO4, decanted, and 
concentrated under reduced pressure onto silica gel. The residue was purified by silica gel 
flash chromatography (15% EtOAc/hexanes) to give methylated allyl ester 5a as a colorless 
oil (100 mg, 95% yield): 1H NMR (500 MHz, CDCl3) δ (a mixture of two rotamers) 7.71 
(d, J = 15.3 Hz, 2H), 7.51 (t, J = 7.4 Hz, 1H), 7.39 (t, J = 6.8 Hz, 2H), 5.96 (ddt, J = 16.6, 
10.4, 6.0 Hz, 1H), 5.48 – 5.17 (m, 4H), 4.71 (d, J = 6.1 Hz, 2H), 4.43 (m, 1H), 3.38 (m, 
1H), 1.49 (s, 9H), 1.47 (s, 3H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 
173.2, 170.9, 170.7, 153.2, 135.0, 132.3, 131.3, 128.4, 128.2, 119.7, 82.1, 67.1, 58.9, 58.1, 
52.8, 50.6, 50.3, 28.3, 19.3; IR (Neat Film, NaCl) 3406, 3065, 2980, 2939, 1714, 1602, 
1450, 1423, 1369, 1288, 1251, 1162, 1134, 1104, 1028, 984, 938, 902, 857, 804, 765, 732, 
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697, 657, 635 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C21H27N2O6 [M+H]
+: 
403.1864, found 403.1868. 
  
 
5-allyl 1-(tert-butyl) 3-benzoyl-5-ethyl-4-oxotetrahydropyrimidine-1,5(2H)-
dicarboxylate (5b). Following the procedure described for the preparation 
of 5a, allyl ester SI-6 (200 mg, 0.52 mmol, 1.0 equiv) was treated with 
cesium carbonate (336 mg, 1.03 mmol, 2.0 equiv) and alkylated with ethyl 
iodide (124 µL, 1.54 mmol, 3.0 equiv) to give, after purification by silica 
gel flash chromatography (dry load SiO2, 15% EtOAc/hexanes), ethylated 
allyl ester 5b as a colorless oil (182 mg, 85% yield): 1H NMR (400 MHz, 
CDCl3) δ (a mixture of two rotamers) 7.70 (d, J = 8.0 Hz, 2H), 7.50 (t, J = 
7.4 Hz, 1H), 7.38 (t, J = 7.7 Hz, 2H), 5.95 (ddt, J = 16.6, 10.4, 6.0 Hz, 1H), 
5.38 (dd, J = 17.2, 1.5 Hz, 1H), 5.31 (d, J = 10.3 Hz, 2H), 5.20 (d, J = 12.5 
Hz, 1H), 4.70 (t, J = 5.5 Hz, 2H), 4.47 – 4.26 (m, 1H), 3.49 (d, J = 13.5 Hz, 
1H), 1.96 (q, J = 7.5 Hz, 2H), 1.49 (s, 9H), 0.96 (t, J = 7.4 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 172.9, 170.4, 
170.1, 169.8, 153.2, 135.0, 132.3, 131.2, 128.4, 128.2, 119.8, 81.9, 66.9, 
57.9, 57.4, 56.7, 47.8, 47.4, 28.3, 26.4, 9.1; IR (Neat Film, NaCl) 2976, 
1703, 1450, 1422, 1367, 1288, 1247, 1156, 1134, 1015, 942, 894, 802, 766, 
718, 696 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C22H29N2O6 
[M+H]+: 417.2020, found 417.2019. 
 
 
 
 
5-allyl 1-(tert-butyl) 3-benzoyl-5-(3-methoxy-3-oxopropyl)-4-
oxotetrahydropyrimidine-1,5(2H)-dicarboxylate (5c). To a suspension of allyl ester SI-
6 (100 mg, 0.26 mmol, 1.0 equiv) and potassium carbonate (178 mg, 1.29 mmol, 5.0 equiv) 
in acetone (1.0 mL) at room temperature was added methyl acrylate (47 μL, 0.52 mmol, 
2.0 equiv). The reaction mixture was stirred for 3.5 h at 55 °C, allowed to cool to room 
temperature, and filtered through a cotton plug. The filter cake was washed with acetone 
(3 x 1 mL) and the combined organic phases were concentrated by under reduced pressure 
onto silica gel. The silica-loaded residue was purified by silica gel flash chromatography 
(19% EtOAc/hexanes) to give pyrimidinone 5c as a colorless oil (101 mg, 83% yield): 1H 
NMR (400 MHz, CDCl3) δ (a mixture of two rotamers) 7.70 (br s, 2H), 7.50 (t, J = 7.4 
Hz, 1H), 7.38 (t, J = 7.7 Hz, 2H), 5.95 (ddt, J = 16.6, 10.3, 6.0 Hz, 1H), 5.38 (dd, J = 17.1, 
1.6 Hz, 1H), 5.32 (d, J = 10.4 Hz, 1H), 5.25 (m, 2H), 4.70 (d, J = 6.0 Hz, 2H), 4.41 (m, 
1H), 3.62 (s, 3H), 3.47 (m, 1H), 2.58 (ddd, J = 16.0, 9.5, 6.4 Hz, 1H), 2.46 – 2.33 (m, 1H), 
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2.21 (ddd, J = 10.0, 6.3, 3.2 Hz, 2H), 1.48 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (a 
mixture of two rotamers) 173.0, 172.9, 169.7, 153.1, 134.9, 132.4, 131.1, 128.4, 128.3, 
120.1, 82.2, 67.2, 58.3, 57.6, 55.6, 51.9, 48.7, 48.2, 29.7, 28.3; IR (Neat Film, NaCl) 2978, 
1704, 1423, 1368, 1248, 1153, 987, 803, 722, 696 cm-1; HRMS (MM: ESI-APCI): m/z 
calc’d for C24H31N2O8 [M+H]+: 475.2075, found 475.2074. 
 
 
5-allyl 1-(tert-butyl) 3-benzoyl-5-(2-chloroallyl)-4-oxotetrahydropyrimidine-1,5(2H)-
dicarboxylate (5d). To a suspension of allyl ester SI-6 (200 mg, 0.51 mmol, 1.0 equiv) 
and tetrabutylammonium iodide (17 mg, 0.05 mmol, 0.1 equiv), in THF (5.1 mL) at 0 °C 
was added NaH (60% in mineral oil, 25 mg, 0.62 mmol, 1.2 equiv). After stirring for 30 
min at 0 °C, 2,3-dichloro-1-propene (95 µL, 1.02 mmol, 2 equiv) was added and the 
reaction mixture heated at 40 °C for 16 h. The reaction was quenched with aqueous NH4Cl 
(10 mL) and extracted with EtOAc (3 x 5 mL). The combined organic phases were dried 
over anhydrous Na2SO4, decanted, and concentrated under reduced pressure onto silica gel. 
The silica-loaded residue was purified by silica gel flash chromatography (10% → 15% 
EtOAc/hexanes) to give 2-chloro-allyl allyl ester 5d as a colorless oil (140 mg, 59% yield): 
1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 8.6 Hz, 2H), 7.51 (s, 1H), 7.39 (t, J = 7.5 Hz, 
2H), 6.07 – 5.90 (m, 1H), 5.71 – 5.48 (m, 1H), 5.33 (m, 4H), 5.03 (d, J = 12.5 Hz, 1H), 
4.85 – 4.43 (m, 3H), 3.58 (mz, 1H), 3.32 (d, J = 15.1 Hz, 1H), 3.03 (d, J = 15f.1 Hz, 1H), 
1.48 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 173.3, 169.9, 
168.7, 153.4, 136.3, 134.9, 132.4, 131.2, 128.7, 128.2, 120.1, 118.8, 82.1, 67.7, 58.5, 57.8, 
55.1, 47.7, 47.2, 41.0, 28.3; IR (Neat Film, NaCl) 2978, 1703, 1632, 1478, 1450, 1423, 
1368, 1289, 1246, 1137, 902, 803, 721, 695, 633 cm-1; HRMS (MM: ESI-APCI): m/z 
calc’d for C23H28ClN2O6 [M+H]
+: 463.1630, found 463.1641. 
 
 
  
 
5-Allyl 1-(tert-butyl) 3-benzoyl-5-benzyl-4-oxotetrahydropyrimidine-1,5(2H)-
dicarboxylate (5e). To a solution of allyl ester SI-6 (100 mg, 0.26 mmol, 1.0 equiv) in 
THF (2.6 mL) at room temperature was added sodium hydride (11 mg, 0.28 mmol, 1.1 
equiv). After stirring for 15 min, benzyl bromide (37 µL, 0.31 mmol, 1.2 equiv) was added. 
The reaction mixture was maintained at room temperature for 22 h and at 55 °C for 24 h. 
The reaction was quenched with aqueous NH4Cl (2 mL) and diluted with EtOAc (2mL). 
The aqueous phase was extracted with EtOAc (3 x 3mL) and the combined organic phases 
were dried over anhydrous Na2SO4, decanted, and concentrated under reduced pressure 
onto silica gel. The silica-loaded residue was purified by silica gel flash chromatography 
(15% EtOAc/hexanes) to give benzylated allyl ester 5e as a colorless oil (94 mg, 76% 
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yield): 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 7.6 Hz, 2H), 7.52 (t, J = 7.5 Hz, 1H), 
7.39 (t, J = 7.5 Hz, 2H), 7.29 – 7.19 (m, 3H), 7.14 (dd, J = 7.4, 2.2 Hz, 2H), 5.95 (ddt, J = 
16.6, 10.4, 6.0 Hz, 1H), 5.44 – 5.19 (m, 3H), 4.73 (m, 3H), 4.56 – 4.37 (m, 1H), 3.50 (d, J 
= 14.0 Hz, 1H), 3.33 (d, J = 13.9 Hz, 1H), 3.14 (d, J = 14.0 Hz, 1H), 1.45 (s, 9H); 13C 
NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 173.1, 170.4, 169.3, 153.2, 135.0, 
134.9, 132.4, 131.3, 130.9, 128.7, 128.7, 128.2, 127.5, 119.9, 81.9, 67.3, 58.0, 57.5, 57.3, 
47.8, 47.2, 38.1, 28.3; IR (Neat Film, NaCl) 3063, 2978, 2935, 1704, 1602, 1479, 1451, 
1418, 1368, 1287, 1251, 1152, 1093, 1002, 927, 902, 857, 804, 764, 727, 697, 635 cm-1; 
HRMS (MM: ESI-APCI): m/z calc’d for C27H31N2O6 [M+H]
+: 479.2177, found 479.2180. 
 
 
 
 
5-allyl 1-(tert-butyl) 3-benzoyl-5-(2-cyanoethyl)-4-oxotetrahydropyrimidine-1,5(2H)-
dicarboxylate (5f). To a solution of allyl ester SI-6 (100 mg, 0.26 mmol, 1.0 equiv) and 
acrylonitrile (34 μL, 0.52 mmol, 2.0 equiv) in acetonitrile (1.3 mL) at room temperature 
was added DBU (1.9 μL, 0.013 mmol, 0.05 equiv). After 22 h at room temperature, the 
reaction mixture was heated to 70 °C for 32 h, allowed to cool to room temperature, and 
treated with additional DBU (1.9 μL, 0.013 mmol, 0.05 equiv). After 2 h at 70 °C, the 
reaction mixture was allowed to cool to room temperature, directly concentrated onto silica 
gel, and purified by silica gel flash chromatography (22% EtOAc/hexanes) to give 
cyanoethylated pyrimidinone 5f as a colorless oil (71.5 mg, 63% yield): 1H NMR (400 
MHz, CDCl3) δ 7.72 (d, J = 7.7 Hz, 2H), 7.53 (t, J = 7.4 Hz, 1H), 7.41 (t, J = 7.6 Hz, 2H), 
5.97 (ddt, J = 16.7, 10.3, 6.1 Hz, 1H), 5.41 (dd, J = 17.4, 1.5 Hz, 1H), 5.36 (d, J = 10.5 Hz, 
1H), 5.28 (m, 2H), 4.74 (m, 2H), 4.41 (d, J = 13.8 Hz, 1H), 3.49 (d, J = 13.8 Hz, 1H), 2.72 
(dt, J = 16.2, 7.9 Hz, 1H), 2.50 (dt, J = 16.6, 7.8 Hz, 1H), 2.20 (t, J = 7.9 Hz, 2H), 1.49 (s, 
9H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 173.0, 169.4, 169.0, 
153.1, 134.6, 132.7, 130.8, 128.4, 128.4, 120.6, 118.9, 82.6, 67.6, 67.6, 58.8, 57.9, 55.1, 
49.0, 48.4, 29.2, 28.4, 13.6; IR (Neat Film, NaCl) 2979, 2250, 1698, 1450, 1423, 1369, 
1286, 1250, 1155, 1030, 939, 857, 803, 718, 696, 635 cm-1; HRMS (MM: ESI-APCI): 
m/z calc’d for C23H31N4O6 [M+NH4]+: 459.2238, found 459.2243. 
 
 
  
 
5-allyl 1-(tert-butyl) 3-benzoyl-5-((benzyloxy)methyl)-4-oxotetrahydropyrimidine-
1,5(2H)-dicarboxylate (5g). Following the procedure described for the preparation of 5a, 
allyl ester SI-6 (200 mg, 0.52 mmol, 1.0 equiv) was treated with sodium hydride (29 mg, 
0.72 mmol, 1.4 equiv) and alkylated with benzyl chloromethyl ether (127 µL, 0.93 mmol, 
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1.8 equiv) to give, after two rounds of purification by silica gel flash chromatography (dry 
load SiO2, 16 → 25% EtOAc/hexanes), BOM-alkylated allyl ester 5g as a colorless oil (57 
mg, 22% yield): 1H NMR (400 MHz, CDCl3) δ 7.73 (t, J = 8.3 Hz, 2H), 7.50 (t, J = 7.9 
Hz, 1H), 7.41 – 7.24 (m, 7H), 5.94 (ddt, J = 16.5, 10.3, 6.0 Hz, 1H), 5.63 (d, J = 12.2 Hz, 
1H), 5.43 – 5.25 (m, 2H), 4.95 (d, J = 12.4 Hz, 1H), 4.74 (dd, J = 13.0, 5.9 Hz, 1H), 4.70 
– 4.36 (m, 4H), 4.07 (d, J = 9.2 Hz, 1H), 3.96 – 3.80 (m, 1H), 3.74 (d, J = 9.3 Hz, 1H), 
1.48 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 173.2, 169.0, 
168.7, 168.3, 153.6, 153.3, 137.5, 134.9, 132.2, 131.3, 131.0, 128.6, 128.1, 128.0, 127.7, 
119.9, 119.7, 81.9, 73.9, 70.0, 67.1, 58.7, 57.9, 57.0, 47.0, 46.7, 28.3; IR (Neat Film, 
NaCl) 2978, 2360, 1704, 1453, 1418, 1368, 1290, 1248, 1153, 1128, 1072, 1003, 904, 857, 
803, 735, 697, 633 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C28H33N2O7 [M+H]+: 
509.2282, found 509.2279. 
 
 
  
 
5-allyl 1-(tert-butyl) 3-benzoyl-5-fluoro-4-oxotetrahydropyrimidine-1,5(2H)-
dicarboxylate (5h). To a solution of allyl ester SI-6 (100 mg, 0.257 mmol, 1.0 equiv) in 
THF (2.6 mL) at room temperature was added sodium hydride (11 mg, 0.28 mmol, 1.1 
equiv). After stirring for 15 min, Selectfluor (109 mg, 0.31 mmol, 1.2 equiv) was added 
and the reaction mixture was stirred for 1.5 h at room temperature. The reaction was 
quenched with aqueous NH4Cl (2 mL) and diluted with EtOAc (2 mL). The aqueous phase 
was extracted with EtOAc (3 x 3 mL) and the combined organic phases were dried over 
anhydrous Na2SO4, filtered and concentrated by reduced pressure onto silica gel. The 
residue was purified by silica gel flash chromatography (4:1 hexanes/EtOAc) to give 
fluorinated allyl ester 5h as a colorless oil (92 mg, 0.226 mmol, 88%); 1H NMR (400 MHz, 
CDCl3) δ (a mixture of two rotamers) 7.67 (s, 2H), 7.52 (t, J = 7.5 Hz, 1H), 7.39 (t, J = 7.6 
Hz, 2H), 5.95 (ddt, J = 16.6, 10.3, 6.0 Hz, 1H), 5.63 – 5.07 (m, 4H), 4.88 – 4.77 (m, 1H), 
4.75 (s, 1H), 4.43 (m, 1H), 3.99 (m, 1H), 1.49 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (a 
mixture of two rotamers) 172.4, 165.3, 164.4, 153.1, 133.8, 132.9, 130.5, 128.6, 128.5, 
120.4, 89.3 (d, JCF = 192.9 Hz, appears as four peaks due to the presence of two rotamers 
and coupling with fluorine), 82.8, 67.8, 59.0, 58.4, 49.2, (d, JCF = 28.3 Hz), 48.4 (d, JCF = 
27.3 Hz), 28.2; IR (Neat Film, NaCl) 2979, 2360, 1770, 1715, 1601, 1478, 1450, 1418, 
1369, 1287, 1252, 1157, 1134, 1072, 1018, 907, 857, 829, 803, 764, 730, 695, 658, 633 
cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C20H27FN3O6 [M+NH4]+: 424.1878, found 
424.1877. 
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5-allyl 1-(tert-butyl) 3-benzoyl-4-oxo-5-(prop-2-yn-1-yl)tetrahydropyrimidine-
1,5(2H)-dicarboxylate 5i. To a solution of allyl ester SI-6 (200 mg, 0.51 mmol, 1.0 equiv) 
in THF (5 mL) at 0 °C was quickly added sodium hydride (23 mg, 0.57 mmol, 1.1 equiv). 
After stirring at 0 °C for 30 minutes, propargyl bromide (111 µL, 1.03 mmol, 2 equiv) was 
added and the reaction mixture was heated to 50 °C. After three hours, more propargyl 
bromide (111 µL, 1.03 mmol, 2 equiv) was added and the reaction was allowed to continue 
for 16 h at 50 °C. The reaction was quenched with aqueous NH4Cl (10 mL) and extracted 
with EtOAc (3 x 5 mL). The combined organic phases were dried over anhydrous Na2SO4, 
decanted, and concentrated under reduced pressure. The crude residue was purified by 
silica gel flash chromatography (50% CH2Cl2/hexanes → 70% CH2Cl2/hexanes →  20% 
EtOAc/hexanes) to afford the propargylated allyl ester 5i as a colorless oil (160 mg, 73% 
yield): 1H NMR (400 MHz, CDCl3) δ 7.74 (s, 2H), 7.50 (d, J = 7.4 Hz, 1H), 7.38 (t, J = 
7.5 Hz, 2H), 5.96 (dd, J = 17.0, 10.6 Hz, 1H), 5.64 (dd, J = 12.4, 2.1 Hz, 1H), 5.39 (d, J = 
17.2 Hz, 1H), 5.33 (d, J = 10.4 Hz, 1H), 5.16 – 4.88 (m, 1H), 4.82 – 4.32 (m, 3H), 4.01 – 
3.63 (m, 1H), 3.03 (d, J = 18.2 Hz, 1H), 2.71 (dd, J = 17.0, 2.7 Hz, 1H), 2.09 (t, J = 2.6 
Hz, 1H), 1.49 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 173.3, 
169.6, 168.6, 153.5, 134.9, 132.4, 131.2, 130.9, 128.6, 128.2, 120.0, 82.2, 78.8, 72.6, 67.5, 
58.9, 58.2, 55.2, 48.2, 28.3, 23.0; IR (Neat Film, NaCl) 3280, 2978, 1704, 1600, 1479, 
1450, 1422, 1368, 1287, 1245, 1155, 1140, 1073, 1016, 929, 904, 856, 803, 765, 733 695, 
656 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C23H27N2O6 [M+H]+: 427.1864, 
found 427.1859. 
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General Procedure for Allylic Alkylation Optimization Screen 
 
Table 1. Optimization of Reaction Parameters 
 
 
 
[a] Screens performed on a 0.04 mmol scale. All reported yields are for isolated products. The ee values 
were determined by chiral SFC analysis. Bz = benzoyl, Boc = tert-butoxycarbonyl, pmdba = bis(4- 
methoxybenzylidene)acetone 
 
In a nitrogen-filled glovebox, an oven-dried 1 dram vial was charged with Pd2(pmdba)3 
(1.7 mg, 0.0015 mmol, 4 mol %), ligand (10 mol %), solvent (1 mL), and a magnetic stir 
bar. The vial was stirred at ambient glovebox temperature (27 °C) for 30 min and then 
substrate 3m (20 mg, 0.04 mmol, 1.0 equiv) was added as a solution in solvent (1.8 mL, 
total concentration 0.014 M). The vial was sealed with a teflon cap and heated to 40 °C. 
When complete consumption of the starting material was observed by thin layer 
chromatography, the reaction mixture was removed from the glovebox and concentrated 
under reduced pressure. The residue was purified by silica gel flash chromatography to 
afford the oxopiperazine 4m.  
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General Procedure for Pd-Catalyzed Decarboxylative Allylic Alkylation Reactions 
 
Please note The absolute configuration for all other products has been inferred by analogy.1 
For respective SFC conditions, please refer to the section Determination of Enantiomeric 
Excess (S. 
 
In a nitrogen-filled glovebox, an oven-dried 1 dram vial or 20 mL scintillation vial was 
charged with Pd2(pmdba)3 or Pd2(dba)3 (4 mol %), (S)-(CF3)3-tBu-PHOX (10 mol %),  
hexane/toluene (2:1), and a magnetic stir bar. The vial was stirred at ambient glovebox 
temperature (27 °C) for 30 min and then the substrate (1.0 equiv) was added as a solution 
in hexane/toluene (2:1, total concentration 0.014 M or 0.033 M). The vial was sealed with 
a teflon cap and heated to 40 °C. When complete consumption of the starting material was 
observed by thin layer chromatography, the reaction mixture was removed from the 
glovebox and concentrated under reduced pressure. The residue was purified by silica gel 
flash chromatography to afford the desired oxopiperazine.  
 
Experimental Procedures and Spectroscopic data for the Pd-Catalyzed 
Decarboxylative Asymmetric Allylic Alkylation of Piperazinone Substrates 
 
 
  
 
tert-butyl (S)-2-allyl-4-benzoyl-3-oxopiperazine-1-carboxylate (4a). Following the 
general procedure, allyl ester 3a (25 mg, 0.064 mmol, 1.0 equiv) in toluene (1.45 mL) was 
added to a solution of Pd2(dba)3 (2.3 mg, 0.0026 mmol, 4 mol %) and (S)-(CF3)3-tBu-
PHOX (3.8 mg, 0.0064 mmol, 10 mol %) in toluene (0.5 mL). Purification by flash 
chromatography (20% EtOAc/hexanes) gave monosubstituted oxopiperazine 4a as a 
yellow oil (21 mg, 90% yield, 92% ee).  1H NMR (400 MHz, CDCl3) δ (a mixture of two 
rotamers) 7.64 – 7.46 (m, 3H), 7.41 (m, 2H), 5.83 (ddt, J = 17.2, 10.0, 7.3 Hz, 1H), 5.22 – 
5.07 (m, 2H), 4.70 (m, 1H), 4.45 – 3.99 (m, 1H), 3.99 – 3.70 (m, 2H), 3.42 (m, 1H), 2.90 
– 2.52 (m, 2H), 1.50 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 
173.6, 170.6, 153.8, 135.3, 133.2, 132.2, 128.3, 128.3, 119.0, 81.3, 58.4, 44.5, 38.1, 37.2, 
28.5. IR (Neat Film, NaCl) 2977, 2930, 1692, 1600, 1450, 1413, 1392, 1366, 1300, 1231, 
1159, 1130, 1008, 973, 920, 856, 795, 762, 729, 696, 656 cm-1; HRMS (MM: ESI-APCI): 
m/z calc’d for C19H25N2O4 [M+H]+: 345.1809, found 345.1810; [α]D23.0 +49.5 (c 1.00, 
CHCl3); SFC conditions: 15% IPA, 2.5 mL/min, Chiralpak AD–H column, λ = 210 nm, 
tR (min): major = 3.741, minor = 2.682. 
 
 
  
 
tert-butyl (S)-2-allyl-4-(4-methoxybenzoyl)-3-oxopiperazine-1-carboxylate (4b). 
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Following the general procedure, anisoyl-protected allyl ester 3b (15 mg, 0.036 mmol, 1.0 
equiv) in toluene (0.6 mL) was added to a solution of Pd2(dba)3 (1.7 mg, 0.0014 mmol, 4 
mol %) and (S)-(CF3)3-tBu-PHOX (2.8 mg, 0.0036 mmol, 10 mol %) in toluene (0.5 mL). 
Purification by flash chromatography (20% EtOAc/hexanes) gave monosubstituted 
oxopiperazine 4b as a light yellow oil (12 mg, 92% yield, 96% ee): 1H NMR (400 MHz, 
CDCl3) δ (a mixture of two rotamers) 7.60 (d, J = 8.9 Hz, 2H), 6.89 (d, J = 8.9 Hz, 2H), 
5.85 (ddt, J = 17.1, 10.0, 7.3 Hz, 1H), 5.24 – 5.04 (m, 2H), 4.69 (m, 1H), 4.19 (m, 1H), 
3.85 (m, 5H), 3.42 (m, 1H), 2.89 – 2.56 (m, 2H), 1.49 (s, 9H); 13C NMR (101 MHz, 
CDCl3) δ 173.0, 170.6, 163.3, 153.9, 133.4, 131.2, 127.1, 118.9, 113.7, 81.3, 58.4, 55.6, 
44.6, 38.3, 37.4, 28.5; IR (Neat Film, NaCl) 2976, 1694, 1605, 1512, 1462, 1416, 1366, 
1315, 1257, 1234, 1170, 1130, 1003, 973, 842, 770 cm-1; HRMS (MM: ESI-APCI): m/z 
calc’d for C20H27N2O5 [M+H]+: 375.1914, found 375.1931; [α]D23.0 +41.7 (c 1.00, CHCl3); 
SFC conditions: 15% IPA, 2.5 mL/min, Chiralpak AD–H column, λ = 210 nm, tR (min): 
major = 4.708, minor = 3.998. 
 
 
  
 
benzyl (S)-2-allyl-4-benzoyl-3-oxopiperazine-1-carboxylate (4c). Following the general 
procedure, Cbz-protected allyl ester 3c (20 mg, 0.047 mmol, 1.0 equiv) in toluene (0.9 mL) 
was added to a solution of Pd2(dba)3 (2.2 mg, 0.0019 mmol, 4 mol %) and (S)-(CF3)3-tBu-
PHOX (3.5 mg, 0.0047 mmol, 10 mol %) in toluene (0.5 mL). Purification by flash 
chromatography (20% EtOAc/hexanes) gave monosubstituted oxopiperazine 4c as a 
colorless oil (15 mg, 83% yield, 99% ee): 1H NMR (500 MHz, CDCl3) δ (a mixture of 
two rotamers) 7.62 – 7.46 (m, 3H), 7.44 – 7.29 (m, 7H), 5.79 (m, 1H), 5.16 (m, 4H), 4.83 
(m, 1H), 4.26 (m, 1H), 3.97 (m, 1H), 3.87 (m, 1H), 3.49 (m, 1H), 2.89 – 2.53 (m, 2H); 13C 
NMR (126 MHz, CDCl3) δ (a mixture of two rotamers) 173.5, 170.2, 154.7, 136.0, 135.2, 
132.9, 132.3, 128.8, 128.6, 128.6, 128.4, 128.3, 119.3, 68.0, 58.4, 44.3, 39.6, 38.9, 37.2, 
36.9; IR (Neat Film, NaCl) 3065, 2951, 1702, 1600, 1449, 1427, 1395, 1362, 1302, 1228, 
1163, 1127, 1015, 975, 922, 796, 761,730, 697, 656 cm
-1; HRMS (MM: ESI-APCI): m/z 
calc’d for C22H23N2O4 [M+H]
+: 379.1652, found 379.1659; [α]D23.0 +66.0 (c 1.0, CHCl3); 
SFC conditions: 30% IPA, 2.5 mL/min, Chiralpak IC column, λ = 210 nm, tR (min): major 
= 4.873, minor = 6.748. 
 
 
  
 
tert-butyl (S)-4-benzoyl-2-(2-chloroallyl)-3-oxopiperazine-1-carboxylate (4d). 
Following the general procedure, 2-chloroallyl ester 3d (20 mg, 0.047 mmol, 1.0 equiv.) 
in hexanes/toluene (2:1, 1.9 mL) was added to a solution of Pd2(pmdba)3 (2.1 mg, 0.0019 
mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (2.8 mg, 0.0047 mmol, 10 mol %) in 
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hexanes/toluene (2:1, 1.5 mL). Purification by silica gel flash chromatography (15% 
EtOAc/hexanes) gave oxopiperazine 4d as a light yellow oil (15 mg, 85% yield, 98% ee). 
1H NMR (400 MHz, CDCl3) δ (A mixture of two rotamers) 7.56 (d, J = 7.8 Hz, 2H), 7.51 
(t, J = 7.4 Hz, 1H), 7.41 (t, J = 7.5 Hz, 2H), 5.30 (s, 1H), 5.24 (s, 1H), 5.06 – 4.88 (m, 1H), 
4.40 – 4.06 (m, 1H), 3.94 (m, 1H), 3.84 (m, 1H), 3.55 – 3.29 (m, 1H), 2.95 (dd, J = 13.1, 
7.4 Hz, 2H), 1.51 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 173.5, 169.8, 153.7, 137.5, 
135.3, 132.3, 128.4, 128.3, 116.8, 81.9, 57.0, 44.6, 41.8, 37.7, 28.4. IR (Neat Film, NaCl) 
2977, 2359, 1694, 1635, 1456, 1418, 1394, 1367, 1284, 1232, 1200, 1158, 1007, 971, 892, 
856, 796, 730, 696 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C19H24ClN2O4 [M+H]+: 
379.1419, found 379.1416; [α]D23.1 +33.8 (c 1.00, CHCl3); SFC conditions: 15% IPA, 2.5 
mL/min, Chiralpak AD–H column, λ = 254 nm, tR (min): major = 4.482, minor = 3.224. 
 
 
  
 
tert-butyl (S)-2-allyl-4-benzoyl-2-methyl-3-oxopiperazine-1-carboxylate (4e). 
Following the general procedure, methylated allyl ester 3e (23 mg, 0.057 mmol, 1.0 equiv) 
in toluene (1.2 mL) was added to a solution of Pd2(pmdba)3 (2.7 mg, 0.0023 mmol, 4 
mol %) and (S)-(CF3)3-tBu-PHOX (3.7 mg, 0.0057 mmol, 10 mol %) in toluene (0.5 mL). 
Purification by flash chromatography (15% EtOAc/hexanes) gave di-substituted 
oxopiperazine 4e as a light yellow oil (17 mg, 85% yield, 96% ee). 1H NMR (500 MHz, 
CDCl3) δ 7.57 – 7.46 (m, 3H), 7.40 (t, J = 7.6 Hz, 2H), 5.81 – 5.67 (m, 1H), 5.17 – 5.13 
(m, 1H), 5.12 (d, J = 1.1 Hz, 1H), 4.16 – 4.02 (m, 1H), 4.03 – 3.91 (m, 1H), 3.79 (ddd, J = 
12.9, 9.0, 3.0 Hz, 1H), 3.53 (ddd, J = 14.1, 9.0, 2.8 Hz, 1H), 3.11 (m, 1H), 2.84 – 2.70 (m, 
1H), 1.77 (s, 3H), 1.53 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 174.3, 172.8, 135.8, 133.1, 
131.8, 128.3, 127.6, 119.5, 81.2, 67.3, 44.2, 42.7, 41.0, 28.6, 25.5; IR (Neat Film, NaCl) 
3076, 2977, 2934, 1692, 1641, 16001,102, 1450, 1392, 1366, 1301, 1230, 1166, 1106, 
1047, 1016, 955, 922, 852, 790, 757, 727, 695 cm-1; HRMS (MM: ESI-APCI): m/z calc’d 
for C20H27N2O4 [M+H]+: 359.1965, found 359.1966; [α]D22.8 +6.5 (c 2.0, CHCl3); SFC 
conditions: 7% IPA, 2.5 mL/min, Chiralpak AD-H column, λ = 210 nm, tR (min): major = 
7.208, minor = 4.714. 
 
 
  
 
tert-butyl (S)-2-allyl-4-(4-methoxybenzoyl)-2-methyl-3-oxopiperazine-1-carboxylate 
(4f). Following the general procedure, anisoyl-protected allyl ester 3f  (25 mg, 0.058 mmol, 
1.0 equiv) in toluene (1.3 mL) was added to a solution of Pd2(pmdba)3 (2.5 mg, 0.0023 
mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (3.4 mg, 0.0058 mmol, 10 mol %) in toluene 
(0.5 mL). Purification by flash chromatography (20% EtOAc/hexanes) gave di-substituted 
oxopiperazine 4f as a light pink oil (19 mg, 86% yield, 96% ee). 1H NMR (400 MHz, 
CDCl3) δ 7.70 – 7.53 (m, 2H), 6.99 – 6.82 (m, 2H), 5.86 – 5.67 (m, 1H), 5.23 – 5.04 (m, 
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2H), 4.01 (dddd, J = 33.5, 13.9, 5.8, 2.8 Hz, 2H), 3.85 (s, 3H), 3.74 (ddd, J = 12.7, 9.0, 2.8 
Hz, 1H), 3.52 (ddd, J = 13.9, 9.0, 2.7 Hz, 1H), 3.20 (s, 1H), 2.80 (ddt, J = 14.0, 7.1, 1.2 
Hz, 1H), 1.77 (s, 3H), 1.52 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 174.1, 172.4, 163.0, 
153.9, 133.2, 130.6, 127.5, 119.4, 113.6, 81.2, 67.1, 55.5, 44.2, 42.8, 41.1, 28.6, 25.6; IR 
(Neat Film, NaCl) 3076, 2977, 2934, 1692, 1641, 16001,102, 1450, 1392, 1366, 1301, 
1230, 1166, 1106, 1047, 1016, 955, 922, 852, 790, 757, 727, 695 cm-1; HRMS (MM: ESI-
APCI): m/z calc’d for C21H29N2O5 [M+H]+: 389.2071, found 389.2083; [α]D22.0 +75.6 (c 
2.9, CHCl3); SFC conditions: 10% IPA, 2.5 mL/min, Chiralpak AD-H column, λ = 210 
nm, tR (min): major = 5.370, minor = 4.278. 
 
 
 
 
tert-butyl (S)-2-allyl-4-(4-methoxybenzoyl)-2-methyl-3-oxopiperazine-1-carboxylate 
(4g). Following the general procedure, di-Bz-protected allyl ester 3g (10 mg, 0.025 mmol, 
1.0 equiv) in toluene (1.3 mL) was added to a solution of Pd2(dba)3 (0.9 mg, 0.00098 mmol, 
4 mol %) and (S)-(CF3)3-tBu-PHOX (1.5 mg, 0.0025 mmol, 10 mol %) in toluene (0.5 mL). 
Purification by flash chromatography (20% EtOAc/hexanes) gave di-substituted 
oxopiperazine 4f as a colorless oil (8 mg, 89% yield, 70% ee). Product identity matched 
previously reported characterization data.4 SFC conditions: 10% MeOH, 2.5 mL/min, 
Chiralpak OJ-H column, λ = 254 nm, tR (min): major = 5.574, minor = 6.659. 
 
 
  
 
tert-butyl (R)-2-allyl-2-benzyl-4-(4-methoxybenzoyl)-3-oxopiperazine-1-carboxylate 
(4h). Following the general procedure, benzylated allyl ester 3h (10 mg, 0.02 mmol, 1.0 
equiv) in hexanes/toluene (2:1, 0.9 mL) was added to a solution of Pd2(pmdba)3 (0.86 mg, 
0.00078 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (1.2 mg, 0.002 mmol, 10 mol %) in 
hexanes/toluene (2:1, 0.5 mL). Purification by flash chromatography (5% → 10% → 15% 
EtOAc/hexanes) gave di-substituted oxopiperazine 4h as a colorless oil (7 mg, 77% yield, 
96% ee): 1H NMR (400 MHz, CDCl3) δ (A mixture of two rotamers) 7.57 (t, J = 8.5 Hz, 
2H), 7.29 (d, J = 5.7 Hz, 3H), 7.22 – 7.07 (m, 2H), 6.91 (d, J = 8.3 Hz, 2H), 5.82 (ddt, J = 
17.0, 9.6, 7.1 Hz, 1H), 5.29 – 5.13 (m, 2H), 3.88 (m, 4H), 3.74 – 3.45 (m, 2H), 3.31 (m, 
1H), 3.16 (d, J = 12.0 Hz, 2H), 2.98 – 2.57 (m, 2H), 1.57 (s, 9H); 13C NMR (101 MHz, 
CDCl3) δ (A mixture of two rotamers) 172.7, 172.3, 172.0, 163.2, 154.7, 153.4, 137.1, 
136.4, 133.1, 132.6, 131.3, 130.4, 128.7, 128.5, 127.5, 127.2, 119.9, 119.7, 113.5, 82.2, 
80.6, 71.7, 55.6, 43.6, 43.3, 42.9, 42.6, 41.8, 29.8, 28.9, 28.6; IR (Neat Film, NaCl) 2975, 
1691, 1604, 1512, 1454, 1365,1309, 1282, 1258, 1167, 1104, 1077, 1021, 993, 925, 839, 
768, 740, 704cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C27H33N2O5 [M+H]+: 
465.2384, found 465.2390; [α]D23.4 +31.0 (c 0.47, CHCl3); SFC conditions: 15% IPA, 2.5 
mL/min, Chiralpak AD-H column, λ = 254 nm, tR (min): major = 7.471, minor = 5.802. 
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tert-butyl (R)-2-allyl-4-benzoyl-2-((benzyloxy)methyl)-3-oxopiperazine-1-carboxylate 
(4i). (Following the general procedure, benzyloxy methyl ether allyl ester 3i (25 mg, 0.049 
mmol, 1.0 equiv) in hexanes/toluene (2:1, 3.0 mL) was added to a solution of Pd2(pmdba)3 
(2.2 mg, 0.0020 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (2.9 mg, 0.0049 mmol, 10 
mol %) in hexanes/toluene (2:1, 0.5 mL). Purification by flash chromatography (15% 
EtOAc/hexanes) gave di-substituted oxopiperazine 4i as a colorless oil (20 mg, 87% yield, 
92% ee): 1H NMR (500 MHz, CDCl3) δ (A mixture of two rotamers) 7.61 (dd, J = 8.2, 
1.4 Hz, 2H), 7.51 – 7.43 (m, 1H), 7.38 – 7.26 (m, 7H), 5.72 (ddt, J = 17.6, 10.3, 7.4 Hz, 
1H), 5.21 – 5.09 (m, 2H), 4.57 (t, J = 13.3 Hz, 3H), 4.32 – 3.63 (m, 5H), 3.25 – 2.93 (m, 
1H), 2.60 (br s, 1H), 1.50 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 173.3, 172.5, 153.4, 
135.6, 132.1, 131.9, 128.6, 128.3, 128.2, 127.9, 127.5, 120.0, 75.1, 74.2, 73.7, 70.6, 43.5, 
38.5, 37.0, 28.6; IR (Neat Film, NaCl) 3064, 2976, 2931, 1692, 1601, 1474, 1452, 1392, 
1365, 1317, 1286, 1251, 1232, 1164, 1102, 1062, 1016, 969, 924, 857, 730, 696, 671 cm-
1; HRMS (MM: ESI-APCI): m/z calc’d for C27H33N2O5 [M+H]+: 465.2384, found 
465.2388; [α]D23.8 –13.9 (c 0.33, CHCl3); SFC conditions: 7% IPA, 2.5 mL/min, Chiralpak 
OJ-H column, λ = 254 nm, tR (min): major = 3.737, minor = 4.398. 
 
 
 
 
tert-butyl (S)-2-allyl-2-(2-cyanoethyl)-4-(4-methoxybenzoyl)-3-oxopiperazine-1-
carboxylate (4j). Following the general procedure, α-cyanoethylated allyl ester 3j (25 mg, 
0.053 mmol, 1.0 equiv) in hexanes/toluene (2:1, 2.8 mL) was added to a solution of 
Pd2(dba)3 (1.9 mg, 0.0021 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (3.1 mg, 0.0053 
mmol, 10 mol %) in hexanes/toluene (2:1, 1.0 mL). Purification by silica gel flash 
chromatography (dry load SiO2, 3:1 hexanes/EtOAc) gave oxopiperazine 4j as a colorless 
oil (20 mg, 88% yield, 97% ee): 1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 8.8 Hz, 2H), 
6.92 (d, J = 8.9 Hz, 2H), 5.79 (ddt, J = 16.6, 10.4, 7.5 Hz, 1H), 5.24 (d, J = 1.7 Hz, 1H), 
5.20 (dd, J = 9.9, 1.9 Hz, 1H), 3.98 – 3.87 (m, 2H), 3.86 (s, 3H), 3.84 – 3.71 (m, 2H), 3.27 
(m, 1H), 2.82 (m, 1H), 2.69 (dd, J = 13.8, 7.4 Hz, 1H), 2.47 (dt, J = 14.1, 7.4 Hz, 1H), 2.32 
(t, J = 7.2 Hz, 2H), 1.53 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 172.4, 171.5, 163.4, 
153.6, 132.0, 131.2, 127.0, 120.6, 119.1, 113.7, 82.0, 69.0, 55.6, 43.8, 43.2, 42.0, 32.3, 
28.5, 13.1; IR (Neat Film, NaCl) 2976, 2933, 2359, 2247, 1694, 1605, 1579, 1512, 1456, 
1366, 1281, 1258 1168, 1113, 1020, 974, 928, 843, 768, 614 cm-1; HRMS (MM: ESI-
APCI): m/z calc’d for C23H30N3O5 [M+H]+: 428.2180, found 428.2182; [α]D23.2 –4.3 (c 
1.0, CHCl3); SFC conditions: 15% IPA, 2.5 mL/min, Chiralpak OD-H column, λ = 210 
nm, tR (min): major = 6.049, minor = 5.143. 
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tert-butyl (S)-2-allyl-4-(4-methoxybenzoyl)-3-oxo-2-(3-oxobutyl)piperazine-1-
carboxylate (4k). Following the general procedure, ketone 3k (25 mg, 0.051 mmol, 1.0 
equiv) in hexanes/toluene (2:1, 2.2 mL) was added to a solution of Pd2(dba)3 (1.9 mg, .002 
mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (3.0 mg, 0.0051 mmol, 10 mol %) in 
hexanes/toluene (2:1, 1.5 mL). Purification by silica gel flash chromatography (dry load 
SiO2, 30% EtOAc/hexanes) gave ketone 4k as a pale yellow oil (17 mg, 73% yield, 97% 
ee); 1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 8.9 Hz, 2H), 6.89 (d, J = 8.9 Hz, 2H), 5.79 
(ddt, J = 14.6, 9.4, 7.5 Hz, 1H), 5.18 (dd, J = 13.8, 1.9 Hz, 2H), 3.92 – 3.81 (m, 6H), 3.80 
– 3.66 (m, 1H), 3.22 (s, 1H), 2.74 (dd, J = 13.8, 7.3 Hz, 1H), 2.72, (m, 1H), 2.50 – 2.27 (m, 
3H), 2.13 (s, 3H), 1.51 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 207.5, 172.6, 172.4, 163.2, 
132.8, 131.0, 127.3, 120.0, 113.6, 81.6, 69.5, 55.6, 43.9, 43.2, 39.1, 32.3, 30.0, 28.6, 24.8; 
IR (Neat Film, NaCl) 2975, 1694, 1605, 1512, 1456, 1392, 1366, 1282, 1258, 1168, 1113, 
1062, 1019, 974, 923, 841, 768 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for 
C24H33N2O6 [M+H]+: 445.2333, found 445.2335; [α]D23.2 +25.1 (c 0.97, CHCl3); SFC 
conditions: 7% IPA, 2.5 mL/min, Chiralpak OD-H column, λ = 235 nm, tR (min): major = 
9.712, minor = 10.434. 
 
 
  
 
tert-butyl (R)-2-allyl-2-((((benzyloxy)carbonyl)amino)methyl)-4-(4-methoxybenzoyl)-
3-oxopiperazine-1-carboxylate (4l). Following the general procedure, aminomethyl allyl 
ester 3l (100 mg, 0.17 mmol, 1.0 equiv) in hexanes/toluene (2:1, 10 mL) was added to a 
solution of Pd2(dba)3 (6.3 mg, 0.0069 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (10 mg, 
0.017 mmol, 10 mol %) in hexanes/toluene (2:1, 2 mL). Purification by silica gel flash 
chromatography (15% → 20% → 30% EtOAc/hexanes) gave di-substituted oxopiperazine 
4l as a yellow oil (60 mg, 65% yield, 92% ee); 1H NMR (400 MHz, CDCl3) δ (a mixture 
of two rotamers) 7.64 (t, J = 8.9 Hz, 2H), 7.44 – 7.23 (m, 5H), 6.89 (d, J = 8.5 Hz, 2H), 
5.79 (dq, J = 16.8, 7.8 Hz, 1H), 5.32 – 4.93 (m, 5H), 4.31 – 3.97 (m, 1H), 3.95 – 3.64 (m, 
7H), 3.64 – 3.45 (m, 1H), 3.45 – 2.87 (m, 1H), 2.64 (dd, J = 14.0, 7.3 Hz, 1H), 1.48 (s, 
9H); 13C NMR (101 MHz, CDCl3) δ 172.6, 172.3, 163.1, 156.4, 153.7, 136.6, 132.2, 
131.1, 128.6, 128.4, 128.3, 127.3, 120.1, 113.6, 70.2, 67.0, 55.6, 46.9, 43.8, 43.2, 39.6, 
28.6;  IR (Neat Film, NaCl) 3357, 2975, 2361, 1694, 1605, 1512, 1456, 1366, 1317, 1283, 
1255, 1169, 1094, 1061, 1020, 923, 841, 768, 699 cm-1; HRMS (MM: ESI-APCI): m/z 
calc’d for C29H36N3O7 [M+H]+: 538.2548, found 538.2543; [α]D22.8 +3.74 (c 2.0, CHCl3); 
SFC conditions: 15% IPA, 2.5 mL/min, Chiralpak OD-H column, λ = 280 nm, tR (min): 
major = 8.425, minor = 7.817. 
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tert-Butyl (R)-2-allyl-4-benzoyl-2-(((tert-butoxycarbonyl)amino)methyl)-3- 
oxopiperazine-1-carboxylate (4m). Following the general procedure, allyl ester 3m (100 
mg, 0.19 mmol, 1.0 equiv) in hexanes/toluene (2:1, 8.0 mL) was added to a solution of 
Pd2(pmdba)3 (8.5 mg, 0.0077 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (11.4 mg, 0.019 
mmol, 10 mol %) in hexanes/toluene (2:1, 4.0 mL). Purification by flash chromatography 
(15% EtOAc/hexanes) gave di-substituted oxopiperazine 4m as a pale yellow foam (85 
mg, 93% yield, 93% ee): 1H NMR (400 MHz, CDCl3) δ (a mixture of two rotamers) 7.61 
(d, J = 7.6 Hz, 2H), 7.51 (tt, J = 7.5, 2.1 Hz, 1H), 7.41 (t, J = 7.5 Hz, 2H), 5.91 – 5.66 (m, 
1H), 5.19 (d, J = 15.6 Hz, 2H), 4.73 (s, 1H), 4.09 – 3.72 (m, 5H), 3.67 (dd, J = 14.0, 7.0 
Hz, 1H), 3.43 – 2.97 (m, 1H), 2.72 – 2.51 (m, 1H), 1.54 (s, 9H), 1.43 (s, 9H); 13C NMR 
(101 MHz, CDCl3) 172.9, 172.8, 155.7, 153.6, 135.8, 132.3, 131.9, 128.2, 128.0, 120.1, 
81.2, 79.7, 70.5, 46.5, 43.7, 43.2, 39.4, 28.6, 28.5; IR (Neat Film, NaCl): = 3374, 2977, 
1694, 1504, 1454, 1392, 1366, 1317, 1286, 1231, 1165, 1094, 1060, 1014, 921, 855, 765, 
729, 696 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C25H36N3O6 [M+H]+: 474.2599, 
found: 474.2602; [α]D23.2 +2.7 (c 1.00, CH3Cl); SFC conditions: 10% IPA, 2.5 mL/min, 
Chiralpak OD-H column, λ = 254 nm, tR (min): major = 4.429, minor = 3.910. 
 
 
Experimental Procedures and Spectroscopic Data for the Pd-Catalyzed 
Decarboxylative Asymmetric Allylic Alkylation of Tetrahydropyrimidinone 
Substrates 
 
 
 
 
tert-butyl (R)-5-allyl-3-benzoyl-5-methyl-4-oxotetrahydropyrimidine-1(2H)-
carboxylate (6a). Following the general procedure, methylated pyrimidinone 5a (15 mg, 
0.037 mmol, 1.0 equiv) in hexanes/toluene (2:1, 1.0 mL) was added to a solution of 
Pd2(pmdba)3 (1.6 mg, 0.0015 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (2.2 mg, 0.0037 
mmol, 10 mol %) in hexanes/toluene (2:1, 1.7 mL). Purification by silica gel flash 
chromatography (13% EtOAc/hexanes) gave α-methyl pyrimidinone 6a as a colorless oil 
(11 mg, 83% yield, 93% ee): 1H NMR (500 MHz, CDCl3) δ 7.57 – 7.46 (m, 3H), 7.40 (t, 
J = 7.6 Hz, 2H), 5.78 (dq, J = 16.9, 8.0 Hz, 1H), 5.31 (d, J = 8.4 Hz, 1H), 5.25 – 5.09 (m, 
3H), 3.69 (d, J = 13.8 Hz, 1H), 3.55 (m, 1H), 2.52 (m, 1H), 2.31 (dd, J = 13.9, 8.0 Hz, 1H), 
1.51 (s, 9H), 1.26 (s, 3H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 
176.8, 176.5, 173.9, 153.7, 135.6, 132.5, 132.1, 128.3, 127.9, 120.0, 81.8, 59.4, 59.0, 50.6, 
49.7, 45.2, 41.0, 28.4, 22.4; IR (Neat Film, NaCl) 2976, 2932, 1698, 1426, 1367, 1286, 
1246, 1136, 1027, 924, 858, 802, 750, 719, 695, 635 cm-1; HRMS (MM: ESI-APCI): m/z 
calc’d for C20H27N2O4 [M+H]+: 359.1965, found 359.1963; [α]D23.2 –25.7 (c 1.0, CHCl3); 
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SFC conditions: 7% IPA, 2.5 mL/min, Chiralpak OJ-H column, λ = 254 nm, tR (min): 
major = 3.209, minor = 2.569. 
 
 
 
 
tert-butyl (R)-5-allyl-3-benzoyl-5-ethyl-4-oxotetrahydropyrimidine-1(2H)-
carboxylate (6b). Following the general procedure, ethylated allyl ester 5b (15 mg, 0.036 
mmol, 1.0 equiv) in hexanes/toluene (2:1, 1.0 mL) was added to a solution of Pd2(pmdba)3 
(1.6 mg, 0.0014 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (2.1 mg, 0.0036 mmol, 10 
mol %) in hexanes/toluene (2:1, 1.6 mL). Purification by silica gel flash chromatography ( 
13% EtOAc/hexanes) gave α-ethyl tetrahydropyrimidinone 6b as a colorless oil (13 mg,  
98% yield, 94% ee); 1H NMR (400 MHz, CDCl3) δ 7.57 – 7.45 (m, 3H), 7.39 (t, J = 7.5 
Hz, 2H), 5.87 – 5.62 (m, 1H), 5.48 – 5.24 (m, 1H), 5.20 – 5.03 (m, 3H), 3.75 (dd, J = 14.0, 
1.4 Hz, 1H), 3.65 – 3.52 (m, 1H), 2.50 (dd, J = 14.2, 6.7 Hz, 1H), 2.27 (d, J = 16.1 Hz, 
1H), 1.79 (dq, J = 14.9, 7.5 Hz, 1H), 1.68 (dq, J = 14.6, 7.4 Hz, 1H), 1.51 (s, 9H), 0.95 (t, 
J = 7.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 175.8, 174.1, 
153.7, 135.8, 132.9, 132.0, 128.3, 128.0, 119.7, 81.7, 59.2, 58.8, 48.6, 48.0, 47.6, 39.1, 
38.6, 28.7, 28.4, 8.4; IR (Neat Film, NaCl) 2976, 2927, 1698, 1426, 1367, 1286, 1263, 
1246, 1136, 1017, 923, 859, 801, 738, 695, 635 cm-1; HRMS (MM: ESI-APCI): m/z 
calc’d for C21H29N2O4 [M+H]+: 373.2122, found: 373.2122; [α]D22.2 –21.0 (c 1.0, CHCl3); 
SFC conditions: 7% IPA, 2.5 mL/min, Chiralpak OJ-H column, λ = 254 nm, tR (min): 
major = 3.956, minor = 2.585. 
 
 
 
 
tert-butyl (R)-5-allyl-3-benzoyl-5-(3-methoxy-3-oxopropyl)-4-
oxotetrahydropyrimidine-1(2H)-carboxylate (6c). Following the general procedure, 
methyl ester pyrimidinone 5c (15 mg, 0.032 mmol, 1.0 equiv) in hexanes/toluene (2:1, 1.0 
mL) was added to a solution of Pd2(pmdba)3 (1.2 mg, 0.0013 mmol, 4 mol %) and (S)-
(CF3)3-tBu-PHOX (1.9 mg, 0.0032 mmol, 10 mol %) in hexanes/toluene (2:1, 1.3 mL). 
Purification by silica gel flash chromatography (15% EtOAc/hexanes) gave methyl ester 
6c as a colorless oil (9.1 mg, 67% yield, 95% ee): 1H NMR (400 MHz, CDCl3) δ 7.50 (dd, 
J = 13.1, 7.2 Hz, 3H), 7.38 (t, J = 7.5 Hz, 2H), 5.73 (dq, J = 16.6, 7.4 Hz, 1H), 5.47 – 5.22 
(m, 1H), 5.22 – 5.04 (m, 3H), 3.66 (m, 5H), 2.49 (dt, J = 12.9, 6.4 Hz, 1H), 2.37 (m, 2H), 
2.31 – 2.19 (m, 1H), 2.14 – 1.91 (m, 2H), 1.51 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (a 
mixture of two rotamers)  175.2, 174.9, 173.9, 173.3, 153.5, 135.6, 132.1, 132.0, 128.4, 
127.9, 120.3, 82.0, 59.2, 58.8, 51.1, 48.7, 47.7, 39.1, 38.8, 30.3, 28.9, 28.3; IR (Neat Film, 
NaCl) 2978, 1738, 1698, 1428, 1368, 1286, 1247, 1147, 925, 856, 802, 764, 696 cm-1; 
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HRMS (MM: ESI-APCI): m/z calc’d for C23H31N2O6 [M+H]+: 431.2177, found 
431.2173; [α]D23.1 +5.5 (c 0.9, CHCl3); SFC conditions: 10% IPA, 2.5 mL/min, Chiralpak 
AD-H column, λ = 254 nm, tR (min): major = 5.591, minor = 6.372. 
 
 
  
 
tert-butyl (S)-5-allyl-3-benzoyl-5-(2-chloroallyl)-4-oxotetrahydropyrimidine-1(2H)-
carboxylate (6d). Following the general procedure, 2-chloropropenyl allyl ester 5d (20 
mg, 0.049 mmol, 1.0 equiv) in hexanes/toluene (2:1, 3.0 mL) was added to a solution of 
Pd2(pmdba)3 (2.1 mg, 0.0020 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (2.9 mg, 0.0049 
mmol, 10 mol %) in hexanes/toluene (2:1, 0.5 mL). Purification by flash chromatography 
(EtOAc/hexanes 15%) gave di-substituted oxopiperazine 6d as a yellow oil (17 mg, 94% 
yield, 94% ee); 1H NMR (400 MHz, CDCl3) δ (a mixture of two rotamers) 7.65 – 7.45 
(m, 3H), 7.40 (t, J = 7.6 Hz, 2H), 5.95 – 5.76 (m, 1H), 5.76 – 5.47 (m, 1H), 5.31 (d, J = 1.3 
Hz, 1H), 5.30 – 5.16 (m, 2H), 4.92 (s, 1H), 4.05 (s, 1H), 3.61 (d, J = 14.0 Hz, 1H), 3.06 (d, 
J = 14.8 Hz, 1H), 2.69 – 2.55 (m, 1H), 2.45 (d, J = 14.5 Hz, 2H), 1.52 (s, 9H); 13C NMR 
(101 MHz, CDCl3) δ (a mixture of two rotamers) 174.4, 173.9, 153.6, 137.5, 135.6, 132.1, 
132.0, 128.3, 128.1, 120.8, 118.1, 82.0, 59.1, 48.2, 47.6, 46.6, 42.8, 42.3, 41.7, 28.4; IR 
(Neat Film, NaCl) 2977, 1698, 1630, 1478, 1426, 1368, 1286, 1246, 1140, 902, 802, 765, 
724, 695, 636 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C22H28ClN2O4 [M+H]+: 
419.1732, found 419.1732; [α]D22.6 +22.2 (c 1.0, CHCl3); SFC conditions: 10% IPA, 2.5 
mL/min, Chiralpak AD-H column, λ = 210 nm, tR (min): major = 4.679, minor = 3.777. 
 
 
 
tert-butyl (S)-5-allyl-3-benzoyl-5-benzyl-4-oxotetrahydropyrimidine-1(2H)-
carboxylate (6e). Following the general procedure, benzylated allyl ester 5e (15 mg, 0.031 
mmol, 1.0 equiv) in hexanes/toluene (2:1, 1.0 mL) was added to a solution of Pd2(pmdba)3 
(1.4 mg, 0.0013 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (1.9 mg, 0.0031 mmol, 10 
mol %) in hexanes/toluene (2:1, 1.2 mL). Purification by silica gel flash chromatography 
(13% EtOAc/hexanes) gave benzyl tetrahydropyrimidinone 6e as a colorless oil (11.5 mg, 
84% yield, 95% ee); 1H NMR (500 MHz, CDCl3) δ 7.58 – 7.49 (m, 3H), 7.42 (t, J = 7.7 
Hz, 2H), 7.31 – 7.24 (m, 3H), 7.20 (d, J = 7.2 Hz, 2H), 5.86 (dddd, J = 16.8, 10.2, 7.9, 6.6 
Hz, 1H), 5.48 – 5.25 (m, 1H), 5.22 (d, J = 10.0 Hz, 1H), 5.21 – 5.14 (m, 1H), 4.87 (d, J = 
11.9 Hz, 1H), 3.89 – 3.72 (m, 1H), 3.55 (d, J = 13.7 Hz, 1H), 3.37 – 3.21 (m, 1H), 2.80 – 
2.68 (m, 1H), 2.65 (dd, J = 14.0, 6.6 Hz, 1H), 2.32 – 2.19 (m, 1H), 1.52 (s, 9H); 13C NMR 
(101 MHz, CDCl3) δ (a mixture of two rotamers) 175.4, 173.9, 153.6, 136.1, 135.6, 132.6, 
132.1, 131.0, 128.5, 128.3, 128.1, 127.1, 120.2, 81.9, 58.8, 49.5, 47.2, 46.5, 41.1, 40.6, 
28.4; IR (Neat Film, NaCl) 2978, 2930, 2360, 1698, 1424, 1368, 1288, 1245, 1142, 1029, 
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924, 856, 802, 718, 696, 636 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C26H31N2O4 
[M+H]+: 435.2278, found: 435.2274; [α]D22.1 –5.6 (c 1.0, CHCl3); SFC conditions: 20% 
IPA, 2.5 mL/min, Chiralpak IC column, λ = 254 nm, tR (min): major = 4.096, minor = 
4.670. 
 
 
  
 
tert-butyl (R)-5-allyl-3-benzoyl-5-(2-cyanoethyl)-4-oxotetrahydropyrimidine-1(2H)-
carboxylate (6f). Following the general procedure, cyanoethylated 
tetrahydropyrimidinone 5f (15 mg, 0.034 mmol, 1.0 equiv) in hexanes/toluene (2:1, 1.0 
mL) was added to a solution of Pd2(pmdba)3 (1.2 mg, 0.0014 mmol, 4 mol %) and (S)-
(CF3)3-tBu-PHOX (2.0 mg, 0.0034 mmol, 10 mol %) in hexanes/toluene (2:1, 1.4 mL). 
Purification by silica gel flash chromatography (20% EtOAc/hexanes) gave cyanoethylated 
tetrahydropyrimidinone 6f as a colorless oil (9.0 mg, 67% yield, 74% ee): 1H NMR (500 
MHz, CDCl3) δ 7.56 – 7.49 (m, 3H), 7.43 (t, J = 7.6 Hz, 2H), 5.75 (dddd, J = 16.8, 10.2, 
7.9, 6.6 Hz, 1H), 5.35 – 5.13 (m, 4H), 3.86 – 3.55 (m, 2H), 2.57 – 2.51 (m, 1H), 2.44 (dd, 
J = 10.0, 5.9 Hz, 2H), 2.32 (dd, J = 14.1, 8.0 Hz, 1H), 2.09 (dt, J = 14.6, 8.5 Hz, 1H), 1.96 
(ddd, J = 14.3, 9.8, 6.2 Hz, 1H), 1.53 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 174.6, 173.7, 
153.4, 135.4, 132.4, 131.2, 128.5, 127.8, 121.2, 119.2, 82.5, 59.4, 48.3, 47.7, 39.1, 31.0, 
28.4, 12.6; IR (Neat Film, NaCl) 2977, 2931, 2248, 1694, 1601, 1478, 1427,1368, 1285, 
1263, 1246, 1141, 1027, 926,901, 857, 802, 763, 721, 696, 636, cm-1; HRMS (MM: ESI-
APCI): m/z calc’d for C22H28N3O4 [M+H]+: 398.2074, found 398.2071; [α]D23.2 +10.0 (c 
1.0, CHCl3); SFC conditions: 30% IPA, 2.5 mL/min, Chiralpak IC column, λ = 254 nm, 
tR (min): major = 3.148, minor = 4.927. 
 
 
  
 
tert-butyl (R)-5-allyl-3-benzoyl-5-((benzyloxy)methyl)-4-oxotetrahydropyrimidine-
1(2H)-carboxylate (6g). Following the general procedure, allyl ester 5g (15 mg, 0.029 
mmol, 1.0 equiv) in hexanes/toluene (2:1, 1.6 mL) was added to a solution of Pd2(pmdba)3 
(1.3 mg, 0.0012 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (1.7 mg, 0.0029 mmol, 10 
mol %) in hexanes/toluene (2:1, 0.5 mL). Purification by flash chromatography (10 → 15% 
EtOAc/hexanes) gave di-substituted oxopiperazine 6g as a yellow oil (13 mg, 87% yield, 
87% ee): 1H NMR (400 MHz, CDCl3) δ 7.69 – 7.51 (m, 2H), 7.51 – 7.42 (m, 1H), 7.42 – 
7.22 (m, 7H), 5.77 (ddt, J = 15.0, 10.3, 7.4 Hz, 1H), 5.54 – 5.49 (m, 1H), 5.28 – 5.10 (m, 
2H), 5.06 (d, J = 12.1 Hz, 1H), 4.63 – 4.40 (m, 2H), 3.94 (m, 1H), 3.82 (d, J = 13.9 Hz, 
1H), 3.75 (d, J = 8.9 Hz, 1H), 3.40 (d, J = 9.0 Hz, 1H), 2.42 (m, 2H), 1.50 (s, 9H); 13C 
NMR (101 MHz, CDCl3) δ 174.7, 173.5, 153.6, 137.8, 135.5, 132.0, 128.6, 128.3, 128.2, 
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127.9, 127.7, 112.0, 81.8, 73.8, 58.8, 50.0, 46.9, 46.3, 38.6, 28.4; IR (Neat Film, NaCl) 
2977, 2926, 2283, 1698, 1641, 1478, 1451, 1426, 1367, 1287, 1246, 1151, 1028, 906, 857, 
801, 740, 697, 635 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C27H32N2O5 [M+H]+: 
465.2384, found 465.2378; [α]D23.4 +11.9 (c 0.67, CHCl3); SFC conditions: 20% IPA, 2.5 
mL/min, Chiralpak IC column, λ = 210 nm, tR (min): major = 5.131, minor = 4.419. 
 
 
 
 
tert-butyl (S)-5-allyl-3-benzoyl-5-fluoro-4-oxotetrahydropyrimidine-1(2H)-
carboxylate (6h). Following the general procedure, fluorinated tetrahydropyrimidinone 5h 
(300 mg, 0.74 mmol, 1.0 equiv) in hexanes/toluene (2:1, 39 mL) was added to a solution 
of Pd2(pmdba)3 (24 mg, 0.022 mmol, 3 mol %) and (S)-(CF3)3-tBu-PHOX (35 mg, 0.059 
mmol, 10 mol %) in hexanes/toluene (2:1, 15 mL). Purification by silica gel flash 
chromatography (15% EtOAc/hexanes) gave fluorinated tetrahydropyrimidinone 6h as a 
pale yellow oil (250 mg, 93% yield, 92% ee); 1H NMR (400 MHz, CDCl3) δ 7.59 (dd, J 
= 8.3, 1.3 Hz, 2H), 7.54 (t, J = 7.4 Hz, 1H), 7.42 (t, J = 7.8 Hz, 2H), 5.82 (ddt, J = 14.9, 
9.6, 7.2 Hz, 1H), 5.66 – 5.34 (m, 1H), 5.29 (s, 1H), 5.25 (d, J = 5.3 Hz, 1H), 5.24 – 5.13 
(m, 1H), 4.13 – 3.72 (m, 2H), 2.81 (td, J = 14.3, 6.9 Hz, 1H), 2.67 (ddd, J = 22.4, 14.5, 7.6 
Hz, 1H), 1.51 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 172.5, 
168.23 (d, JCF = 23.6 Hz), 153.4, 134.3, 132.7, 129.7, 129.6, 128.5, 128.5, 128.3, 128.0, 
121.4, 92.2 (d, JCF = 197.0 Hz, appears as four peaks due to the presence of two rotamers 
and coupling with fluorine), 82.4, 57.7, 49.4 (appears as four poorly resolved peaks due to 
the presence of two rotamers and coupling with fluorine), 38.2 (d, JCF = 22.8 Hz), 28.3; IR 
(Neat Film, NaCl) 2978, 1710, 1416, 1368, 1286, 1245, 1158, 1137, 906, 858, 801, 749, 
723, 694, 662 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C19H24N2O4 [M+H]+: 
363.1715, found: 363.1713; [α]D21.8 –28.6 (c 0.96, CHCl3); SFC conditions: 10% IPA, 2.5 
mL/min, Chiralpak IC column, λ = 254 nm, tR (min): major = 6.226, minor = 5.041. 
 
 
  
 
tert-butyl (S)-5-allyl-3-benzoyl-4-oxo-5-(prop-2-yn-1-yl)tetrahydropyrimidine-1(2H)-
carboxylate (6i). Following the general procedure, propargylated allyl ester 5i (20 mg, 
0.047 mmol, 1.0 equiv) in hexanes/toluene (2:1, 2.8 mL) was added to a solution of 
Pd2(pmdba)3 (2.1 mg, 0.0019 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (2.8 mg, 0.0047 
mmol, 10 mol %) in hexanes/toluene (2:1, 0.5 mL). Purification by flash chromatography 
(EtOAc/hexanes 5% → 10% → 15%) gave propargyl tetrahydropyrimidinone 6i as a 
yellow oil (15 mg, 83% yield, 90% ee): 1H NMR (400 MHz, CDCl3) δ 7.58 (s, 1H), 7.50 
(t, J = 7.4 Hz, 2H), 7.39 (t, J = 7.5 Hz, 2H), 5.89 – 5.68 (m, 1H), 5.42 (s, 1H), 5.31 – 4.98 
(m, 3H), 4.15 – 3.57 (m, 2H), 2.61 (dd, J = 16.9, 2.7 Hz, 2H), 2.42 (dd, J = 16.9, 2.7 Hz, 
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2H), 2.11 (t, J = 2.6 Hz, 1H), 1.54 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (a mixture of 
two rotamers) 174.3, 173.7, 153.6, 135.4, 132.2, 131.8, 128.3, 128.2, 120.6, 82.0, 79.6, 
72.4, 59.3, 58.9, 48.2, 47.8, 40.1, 39.6, 28.4, 25.1; IR (Neat Film, NaCl) 3271, 2978, 2930, 
1698, 1478, 1450, 1425, 1368, 1284, 1247, 1139, 1028, 927, 854, 802, 764, 720, 695, 635 
cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C22H27N2O4 [M+H]+: 383.1965, found 
383.1973; [α]D23.0 +22.1 (c 0.47, CHCl3); SFC conditions: 10% IPA, 2.5 mL/min, 
Chiralpak AD-H column, λ = 210 nm, tR (min): major = 4.769, minor = 4.399. 
 
 
Experimental Procedure for the Gram Scale Decarboxylative Asymmetric Allylic 
Alkylation of Benzyl Tetrahydropyrimidinone 5e 
 
 
 
 
tert-butyl (S)-5-allyl-3-benzoyl-5-benzyl-4-oxotetrahydropyrimidine-1(2H)-
carboxylate (6e). In a nitrogen-filled glovebox, a 250 mL schlenk flask was charged with 
Pd2(pmdba)3 (69 mg, 0.063 mmol, 4 mol %), (S)-(CF3)3-tBu-PHOX (99 mg, 0.17 mmol, 8 
mol %), hexane/toluene (2:1, 50 mL), and a magnetic stir bar. The flask was stirred at 
ambient glovebox temperature (27 °C) for 30 min and then 5e (1g, 2.1 mmol, 1.0 equiv) 
was added as a solution in hexane/toluene (2:1, 100 mL, total concentration 0.014M). The 
flask was sealed with a Kontes valve, removed from the glovebox, and heated to 40 °C for 
16 h. The solution was concentrated under reduced pressure and purified by silica gel flash 
chromatography (15% EtOAc/hexanes) to give benzyl tetrahydropyrimidinone 6e as a 
yellow oil (780 mg, 87% yield, 95% ee); spectroscopic data vide supra.  
 
 
Experimental Procedures for the Transformations of Decarboxylative Allylic 
Alkylation Products 
 
 
 
tert-butyl (R)-((2-allyl-4-benzoyl-3-oxopiperazin-2-yl)methyl)carbamate (8). 
Trifluoroacetic acid (114 µL, 1.5 mmol, 20 equiv) was added dropwise to a solution of 
methylcarbamate oxopiperazine 4m (35 mg, 0.07 mmol, 1.0 equiv) in CH2Cl2 
(0.74 mL) at 0 °C. The reaction mixture was allowed to warm up to room temperature, 
stirred for 3 h and concentrated under reduced pressure. The residue was repeatedly taken 
up in CH2Cl2 (1.0 mL) and concentrated, four times. The crude residue 
was then purified by silica gel flash chromatography (10% MeOH/CH2Cl2) to yield 
deprotected oxopiperazine 8 as a pale yellow foam (27 mg, 73% yield); 1H NMR (400 
MHz, CDCl3) δ 7.48 (t, J = 8.0 Hz, 3H), 7.37 (t, J = 7.4 Hz, 2H), 5.66 (dd, J = 16.0, 8.8 
Hz, 1H), 5.30 (d, J = 9.8 Hz, 1H), 5.25 (d, J = 16.8 Hz, 1H), 3.99 – 3.79 (m, 1H), 3.73 – 
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3.55 (m, 1H), 3.44 – 3.16 (m, 2H), 3.05 (d, J = 13.2 Hz, 1H), 2.89 (d, J = 11.6 Hz, 1H), 
2.76 (dd, J = 14.0, 7.0 Hz, 1H), 2.45 (dd, J = 14.2, 7.1 Hz, 1H); 13C NMR (101 MHz, 
CDCl3) δ 173.7, 172.4, 135.5, 132.2, 129.7, 128.4, 128.0, 122.5, 62.0, 47.0, 43.5, 39.7, 
38.1; IR (Neat Film, NaCl) 2976, 1682, 1470, 1282, 1203, 1135, 926, 836, 799, 722, 696 
cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C15H20N3O4 [M+H]+: 274.1550, found 
274.1555; [α]D22.3 +15.1 (c 1.0, CHCl3). 
 
 
 
 
tert-butyl (R)-2-allyl-2-(((tert-butoxycarbonyl)amino)methyl)-3-oxopiperazine-1-
carboxylate (9). LiOH monohydrate (2.5 mg, 0.06 mmol, 1.4 equiv) was added in one 
portion to a solution of methylcarbamate oxopiperazine 4m (20 mg, 0.04 mmol, 1.0 equiv) 
in methanol/water (1:1, 1.8 mL) at room temperature. The reaction mixture was stirred for 
1 h, diluted with EtOAc (2 mL) and washed with saturated aqueous NaHCO3 (2 mL). The 
aqueous phase was extracted with EtOAc (3x3 mL) and the combined organic phases were 
washed with brine (3 mL), dried over anhydrous Na2SO4, decanted, and concentrated under 
reduced pressure onto silica gel. The silica-loaded residue was purified by silica gel flash 
chromatography (hexanes/EtOAc 1:1) to yield lactam 9 as a white foam (14 mg, 92% 
yield): 1H NMR (400 MHz, CDCl3) δ 6.96 (s, 1H), 5.72 (ddt, J = 17.2, 10.2, 7.4 Hz, 1H), 
5.16 – 5.04 (m, 2H), 4.88 (t, J = 6.9 Hz, 1H), 4.26 – 3.91 (m, 1H), 3.82 (s, 1H), 3.60 (dd, J 
= 14.0, 5.9 Hz, 1H), 3.50 (s, 1H), 3.39 – 2.83 (m, 3H), 2.62 (s, 1H), 1.52 (s, 9H), 1.41 (s, 
9H); 13C NMR (101 MHz, CDCl3) δ 172.7, 155.7, 153.9, 132.7, 119.2, 81.2, 79.3, 69.1, 
46.0, 43.1, 40.9, 38.9, 28.6, 28.5; IR (Neat Film, NaCl) 3337, 2977, 2360, 1698, 1520, 
1367, 1243, 1168, 1085, 1058, 919, 866, 768, 733 cm-1; HRMS (MM: ESI-APCI): m/z 
calc’d for C18H32N3O5 [M+H]+: 370.2336, found 370.2337; [α]D21.9 –5.7 (c 1.0, CHCl3). 
 
 
tert-butyl (S)-2-allyl-2-(((tert-butoxycarbonyl)amino)methyl)piperazine-1-
carboxylate (10). To a solution of lactam 9 (50 mg, 0.14 mmol, 1 equiv) in THF (1.4 mL) 
at 0 °C was quickly added LAH (8 mg, 0.2 mmol, 1.5 equiv) in one portion. The mixture 
was stirred at room temperature and three portions of LAH (8 mg, 0.2 mmol, 1.5 equiv) 
were added over four hours until all starting material was consumed as determined by TLC 
analysis. The reaction mixture was then cooled to 0 °C and diluted with Et2O. H2O (40 
µL), 15% aqueous NaOH (40 µL), and H2O (120 µL) were added successively at 0 °C. The 
mixture was stirred for 5 minutes at room temperature and then MgSO4 was added. The 
mixture was stirred for another 5 minutes at room temperature and then filtered over a pad 
of celite, rinsing with EtOAc. The solvent was concentrated under reduced pressure and 
the crude residue was purified by silica gel flash chromatography (MeOH/CH2Cl2, 1 → 2 
→  4%) to afford piperazine 10 as a colorless oil (30 mg, 63% yield); 1H NMR (400 MHz, 
CDCl3) δ 5.84 – 5.66 (m, 1H), 5.28 – 5.01 (m, 3H), 3.75 (dd, J = 14.1, 5.6 Hz, 1H), 3.62 
(dt, J = 13.6, 4.2 Hz, 1H), 3.35 (dd, J = 14.1, 7.3 Hz, 1H), 3.24 (ddd, J = 13.6, 9.8, 3.8 Hz, 
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1H), 3.02 – 2.91 (m, 1H), 2.85 (t, J = 11.1 Hz, 2H), 2.79 – 2.63 (m, 2H), 2.57 – 2.26 (m, 
2H), 1.46 (s, 9H), 1.44 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 156.8, 156.0, 133.1, 119.1, 
80.6, 79.6, 59.9, 50.8, 46.2, 45.1, 42.3, 38.1, 28.6, 28.5; IR (Neat Film, NaCl) 3789, 3662, 
3451, 3341, 3074, 2976, 2930, 2284, 1693, 1641, 1502, 1453, 1391, 1365, 1298, 1249, 
1169, 1085, 996, 914, 859, 771 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for 
C18H34N3O4 [M+H]+: 356.2544, found 356.2549; [α]D22.8 +5.3 (c 0.67, CHCl3). 
 
 
 
 
(S)-1-benzoyl-3-methyl-3-propylpiperazin-2-one 11. Piperazinone 4e (80 mg, 0.22 
mmol, 1 equiv) was dissolved in MeOH (2.2 mL). The reaction flask was purged with 
Argon before adding Pd/C (10%, 24 mg, 0.022 mmol, 0.1 equiv). The flask was evacuated 
and filled with H2 three times, and then sparged with H2 for 5 minutes. The reaction was 
stirred at room temperature for 6 hours before being filtered through a pad of silica gel 
while rinsing with EtOAc. The crude hydrogenated product was then dissolved in CH2Cl2 
(2.2 mL) and TFA (171 µL, 2.23 mmol, 10 equiv) was added. The reaction was stirred for 
16 hours and then quenched with saturated aqueous NaHCO3 (5 mL). The solution was 
extracted with EtOAc (3x5 mL), dried over Na2SO4, decanted, and concentrated under 
reduced pressure. The crude piperazinone was purified by silica gel flash chromatography 
(2.5 → 5% MeOH/CH2Cl2) to afford the desired product 11 (55 mg, 94% yield over two 
steps): 1H NMR (400 MHz, CDCl3) δ 7.58 – 7.50 (m, 2H), 7.54 – 7.46 (m, 1H), 7.46 – 
7.36 (m, 2H), 3.92 (ddd, J = 12.6, 5.4, 4.6 Hz, 1H), 3.81 (ddd, J = 12.5, 6.7, 5.4 Hz, 1H), 
3.32 – 3.18 (m, 2H), 1.92 (ddd, J = 13.6, 12.1, 4.7 Hz, 1H), 1.62 (ddd, J = 13.6, 12.2, 4.5 
Hz, 1H), 1.42 (s, 3H), 1.54 – 1.23 (m, 2H), 0.96 (t, J = 7.3 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 176.7, 174.7, 136.4, 131.6, 128.3, 127.5, 61.2, 48.2, 41.2, 38.7, 25.0, 16.9, 14.5; 
IR (Neat Film, NaCl) 3331, 2960, 2872, 1681, 1600, 1448, 1378, 1284, 1202, 1176, 1152, 
1112, 966, 794, 726, 694, 669 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C15H21N2O2 
[M+H]+: 261.1598, found 261.1596; [α]D22.6 –59.6 (c 1.35, CHCl3). 
 
 
 
 
(R)-4-benzoyl-6-propyl-1,4-diazabicyclo[4.2.0]octane-5,8-dione (12). To a 10 mL 
round-bottom flask was added Pd(OPiv)2 (3 mg, 0.0096 mmol, 0.1 equiv), AgOPiv7 (60 
mg, 0.29 mmol, 3 equiv), Xantphos (6 mg, 0.0096 mmol, 0.1 equiv), and 1,4-benzoquinone 
(21 mg, 0.19 mmol, 2 equiv). A solution of piperazine 11 (25 mg, 0.096 mmol, 1 equiv) in 
toluene (1 mL) was then added and the flask was evacuated and filled with carbon 
monoxide three times. The flask was then stirred at 80 °C for 16 hours. The reaction 
mixture was allowed to cool to room temperature, diluted with EtOAc, and filtered through 
celite while rinsing with additional EtOAc. The solvent was concentrated under reduced 
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pressure onto silica gel and then purified by silica gel flash chromatography (2:1 
hexanes/EtOAc) to provide the β-lactam 12 and as a light yellow oil (15 mg, 55% yield): 
1H NMR (400 MHz, CDCl3) δ (5:1 ratio of desired product and an inseparable isomer 
resulting from insertion into another β-C−H) 7.56 – 7.51 (m, 3H), 7.46 – 7.40 (m, 2H), 
4.51 (ddd, J = 14.0, 6.1, 2.9 Hz, 1H), 3.94 (ddt, J = 12.3, 10.8, 5.7 Hz, 1H), 3.78 – 3.67 (m, 
1H), 3.40 (dddd, J = 12.3, 4.8, 2.8, 1.5 Hz, 1H), 3.27 – 3.10 (m, 2H), 1.98 (ddd, J = 14.2, 
11.2, 5.5 Hz, 1H), 1.87 (ddd, J = 14.2, 11.0, 5.7 Hz, 1H), 1.59 – 1.40 (m, 2H), 1.00 (t, J = 
7.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 174.2, 173.2, 169.1, 135.1, 132.6, 128.6, 
128.3, 59.7, 46.7, 41.5, 39.7, 37.8, 17.7, 14.3; IR (Neat Film, NaCl) 3374, 2961, 1760, 
1688, 1600, 1505, 1449, 1350, 1318, 1279, 1228, 1183, 1151, 1110, 963, 936, 796, 726, 
694, 662 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C16H19N2O3 [M+H]+: 287.1390, 
found 287.1385; [α]D23.5 –12.8 (c 0.47, CHCl3). 
 
 
  
 
(S)-2-benzyl-2-(((tert-butoxycarbonyl)amino)methyl)pent-4-enoic acid (13). To a 
solution of benzyl tetrahydropyrimidinone 6e (200 mg, 0.46 mmol, 1 equiv) in methylene 
chloride (4.6 mL) was added TFA (352 µL, 4.6 mmol, 10 equiv) dropwise at room 
temperature. The solution was stirred for 24 hours at room temperature and then quenched 
with aqueous NaHCO3 (10 mL). The layers were separated and the aqueous layer was 
extracted with CH2Cl2 (4 x 5 mL). The combined organic layers were dried over Na2SO4, 
filtered, and concentrated under reduced pressure.  
The crude residue was dissolved in MeOH/H2O (1:1, 5 mL) and LiOH monohydrate 
(290 mg, 6.9 mmol, 15 equiv) was added. The reaction mixture was heated to 80 °C for 60 
hours and then allowed to cool to room temperature. Then, NEt3 (77 µL, 0.55 mmol, 1.2 
equiv) and Boc2O (110 mg, 0.51 mmol, 1.1 equiv) were added successively at room 
temperature. The reaction was stirred for 1 hour at room temperature and then acidified 
with 1 M HCl (4 mL). The solution was extracted with EtOAc (3 x 5 mL). The combined 
organic layers were dried over Na2SO4.  
The crude Boc-protected β-amino acid was taken up in DMF (2.3 mL). K2CO3 (95 
mg, 0.69 mmol, 1.5 equiv) and BnBr (66 µL, 0.55 mmol, 1.2 equiv) were added at room 
temperature. The reaction was stirred at room temperature for 1 hour and then quenched 
with saturated aqueous NH4Cl. The solution was extracted with EtOAc (3 x 5 mL) and the 
combined organic layers were concentrated under reduced pressure and placed under high 
vacuum until trace DMF had evaporated. The residue was taken up in CH2Cl2, concentrated 
under reduced pressure onto silica gel and purified by silica gel flash chromatography (5 
→ 10% EtOAc/hexanes) to afford protected β2,2-amino acid 13 as a white solid (80 mg, 
40% yield): 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.27 (m, 5H), 7.20 (dd, J = 4.9, 1.9 Hz, 
3H), 7.10 – 6.93 (m, 2H), 5.92 – 5.75 (m, 1H), 5.18 – 5.04 (m, 4H), 4.96 – 4.81 (m, 1H), 
3.34 (qd, J = 14.0, 6.5 Hz, 2H), 2.98 (d, J = 13.8 Hz, 1H), 2.86 (d, J = 13.8 Hz, 1H), 2.49 
(ddt, J = 14.2, 6.7, 1.4 Hz, 1H), 2.31 (ddt, J = 14.2, 7.9, 1.1 Hz, 1H), 1.43 (s, 9H); 13C 
NMR (101 MHz, CDCl3) δ 175.1, 156.1, 136.6, 135.6, 133.4, 130.2, 128.8, 128.6, 128.5, 
128.4, 126.9, 119.2, 79.4, 66.8, 51.6, 44.1, 41.0, 38.8, 28.5; IR (Neat Film, NaCl) 3452, 
BnO
O
BocHN
Bn
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3065, 3031, 2977, 2930, 1721, 1640, 1604, 1503, 1454, 1391, 1365, 1245, 1169, 1094, 
1030z, 994, 917, 859, 776, 741, 700 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for 
C25H32NO4 [M+H]+: 410.2326, found 410.2324; [α]D23.4 +3.47 (c 1.0, CHCl3). 
 
 
(R)-2-allyl-2-(aminomethyl)pentanedioic acid (14). To a solution of methyl ester 
tetrahydropyrimidinone 6c (140 mg, 0.325 mmol, 1 equiv) in CH2Cl2 (3.1 mL, 0.1 M) was 
added TFA (250 µL, 3.25 mmol, 10 equiv) dropwise at room temperature. The solution 
was stirred for 24 h at room temperature and then concentrated under reduced pressure. 
Remaining TFA was removed with by azeotroping with CH2Cl2 three times. The crude 
residue was dissolved in MeOH/H2O (1:1, 3.1 mL, 0.1 M) and LiOH monohydrate (205 
mg, 4.89 mmol, 15 equiv) was added. The reaction mixture was heated to 80 °C for 16 h 
and then allowed to cool to room temperature. The reaction mixture was then acidified with 
4 M HCl in dioxanes (~1 mL) until pH 1. Then, the solvent was concentrated under reduced 
pressure, resulting in precipitation of a white solid. A minimal amount of DMSO (~1 mL) 
was added to resolvate this precipitate. This solution was subjected to purification by 
reverse phase preparatory HPLC (0 → 40% MeCN/H2O gradient over 11 minutes, 20x250 
mm C18 column, 25 mL/min flow rate) to yield β-amino acid 14 (30 mg, 46% yield) as a 
colorless oil. Note: HPLC fractions were spotted onto a silica TLC plate and eluted in (n-
BuOH/H2O/EtOAc/AcOH, 1:1:1:1), then stained with ninhydrin to identify product-
containing fractions. LC-MS was used to verify the fractions containing product. Note: 
HPLC H2O solvent contained 0.25% TFA. 1H NMR (400 MHz, Methanol-d4) δ 5.88 – 
5.68 (m, 1H), 5.32 – 5.13 (m, 2H), 3.18 – 2.99 (m, 2H), 2.51 (ddt, J = 14.4, 7.1, 1.3 Hz, 
1H), 2.47 – 2.33 (m, 3H), 1.99 (td, J = 7.6, 1.3 Hz, 2H); 13C NMR (101 MHz, MeOD) δ 
176.7, 176.6, 133.1, 120.6, 48.3, 43.5, 39.1, 29.38, 29.35; IR (Neat Film, NaCl) 2924, 
1678, 1198, 1138 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C9H16NO4 [M+H]+: 
202.1074, found 202.1075; [α]D22.7 –3.51 (c 1.0, MeOH). 
 
 
(S)-2-allyl-2-(aminomethyl)-4-chloropent-4-enoic acid (15). To a solution of chloroallyl 
tetrahydropyrimidinone 6d (30 mg, 0.072 mmol, 1 equiv) in CH2Cl2 (700 µL, 0.1 M) was 
added TFA (55 µL, 0.72 mmol, 10 equiv) dropwise at room temperature. The solution was 
stirred for 5 h at room temperature and then concentrated under reduced pressure. 
Remaining TFA was removed with by azeotroping with CH2Cl2 three times. The crude 
residue was dissolved in MeOH/H2O (1:1, 700 µL, 0.1 M) and LiOH monohydrate (45 mg, 
1.07 mmol, 15 equiv) was added. The reaction mixture was heated to 80 °C for 16 h and 
then allowed to cool to room temperature. The reaction mixture was then acidified with 4 
M HCl in dioxane (~1 mL) until pH 1. Then, the solvent was concentrated under reduced 
pressure, resulting in precipitation of a white solid. A minimal amount of DMSO (~1 mL) 
was added to resolvate this precipitate. This solution was subjected to purification by 
HO
NH2
O
O OH
HO
NH2
O
Cl
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reverse phase preparatory HPLC (10 → 40% MeCN/H2O gradient over 11 minutes, 20x250 
mm C18 column, 25 mL/min flow rate) to yield chloroallyl β-amino acid 15 (10 mg, 69% 
yield) as a colorless oil. Note: HPLC fractions were spotted onto a silica TLC plate and 
eluted in (n-BuOH/H2O/EtOAc/AcOH, 1:1:1:1), then stained with ninhydrin to identify 
product-containing fractions. LC-MS was used to verify the fractions containing product. 
Note: HPLC H2O solvent contained 0.25% TFA. 1H NMR (600 MHz, Methanol-d4) δ 
5.84 (td, J = 17.2, 7.3 Hz, 1H), 5.40 (s, 2H), 5.28 – 5.18 (m, 2H), 3.29 (d, J = 13.5 Hz, 1H), 
3.12 (d, J = 13.5 Hz, 1H), 2.94 (d, J = 15.1 Hz, 1H), 2.77 (d, J = 14.8 Hz, 1H), 2.57 (dd, J 
= 14.5, 7.0 Hz, 1H), 2.47 (dd, J = 14.5, 7.8 Hz, 1H); 13C NMR (101 MHz, MeOD) δ 176.6, 
138.2, 133.1, 120.8, 118.7, 48.4, 44.2, 43.5, 39.6. Note: A 1H-13C HMBC experiment 
revealed the chemical shift of the chiral quaternary carbon to be at 48.4 ppm, obscured by 
the CD3OD resonance. IR (Neat Film, NaCl) 2926, 1673, 1432, 1200, 1140, 900, 836, 
800, 722 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C9H15ClNO2 [M+H]+: 204.0786, 
found 204.0787; [α]D22.5 –4.64 (c 0.67, MeOH). 
 
 
(S)-2-(aminomethyl)-2-fluoropent-4-enoic acid (16). To a solution of fluoro 
tetrahydropyrimidinone 6h (20 mg, 0.055 mmol, 1 equiv) in 1:1 MeOH/H2O (550 µL, 0.1 
M) at room temperature was added KOH (31 mg, 0.55 mmol, 10 equiv). The cloudy 
solution became clear over seconds and was stirred for 5 min at room temperature until 
TLC analysis showed complete consumption of starting material. AcOH (~100 µL) was 
added to acidify the solution, which was then extracted with CH2Cl2 three times. The 
combined organic layers were dried with Na2SO4 and then concentrated under reduced 
pressure.  
HCl was generated in situ by adding AcCl (205 µL, 2.87 mmol, 52 equiv) dropwise 
to a separate 1 dram vial containing MeOH (550 µL) at 0 °C. This HCl solution was stirred 
for 5 min at 0 °C and was then transferred by pipette into a 1 dram vial containing the crude 
saponified residue. The reaction was stirred at rt for 2 h and was then concentrated under 
reduced pressure. The crude residue was dissolved in 1:1 H2O/MeCN (2.5 mL) and was 
then subjected to purification by reverse phase preparatory HPLC (0 → 40% MeCN/H2O 
gradient over 11 minutes, 20x250 mm C18 column, 25 mL/min flow rate) to yield fluoro β-
amino acid 16 (5.0 mg, 65% yield) as a colorless oil. Note: HPLC fractions were spotted 
onto a silica TLC plate and eluted in (n-BuOH/H2O/EtOAc/AcOH, 1:1:1:1), then stained 
with ninhydrin to identify product-containing fractions. LC-MS was used to verify the 
fractions containing product. Note: HPLC H2O solvent contained 0.25% TFA.  1H NMR 
(600 MHz, Methanol-d4) δ 5.80 (ddt, J = 17.3, 10.1, 7.2 Hz, 1H), 5.30 – 5.17 (m, 2H), 
3.51 (dd, J = 26.1, 13.9 Hz, 1H), 3.38 – 3.32 (dd, J = 26.1, 13.9 Hz, 1H), 2.81 – 2.63 (m, 
2H); 13C NMR (101 MHz, MeOD) δ 171.1 (d, JCF = 26.2 Hz), 130.7, 121.3, 95.0 (d, JCF 
= 190.2 Hz), 44.74 (d, JCF = 22.1 Hz), 40.44 (d, JCF = 22.1 Hz); IR (Neat Film, NaCl) 
2924, 1674, 1422, 1202, 1141, 931, 798, 722 cm-1; HRMS (MM: ESI-APCI): m/z calc’d 
for C6H11NO2 [M+H]+: 148.0768, found 148.0770; [α]D22.5 –2.47 (c 0.33, MeOH). 
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Determination of Enantiomeric Excess 
 
Please note racemic products were synthesized according to the general procedure, using 
achiral GlyPHOX ligand instead of (S)-(CF3)3-tBu-PHOX.3  
 
 
 
Entry Product AssayConditions
Retention time
of major
isomer (min)
Retention time
of minor
isomer (min)
%ee
1
SFC
Chiralpak AD-H
15% iPrOH
isocratic, 2.5 mL/min
3
4
5
6
7
8
SFC
Chiralpak IC
30% iPrOH
isocratic, 2.5 mL/min
4.873 6.748 99%
SFC
Chiralpak AD-H
15% iPrOH
isocratic, 2.5 mL/min
3.224 98%
SFC
Chiralpak AD-H
7% iPrOH
isocratic, 2.5 mL/min
7.208 4.714 96%
SFC
Chiralpak OJ-H
10% MeOH
isocratic, 2.5 mL/min
6.659 70%
SFC
Chiralpak AD-H
10% iPrOH
isocratic, 2.5 mL/min
4.278 96%
SFC
Chiralpak AD-H
15% iPrOH
isocratic, 2.5 mL/min
5.802 96%
3.741 2.682 92%
2
SFC
Chiralpak AD-H
15% iPrOH
isocratic, 2.5 mL/min
4.708 3.998 96%
BzN
NBoc
O
AnN
NBoc
O
BzN
NCbz
O
BzN
NBoc
O
Cl
BzN
NBoc
O Me
BzN
NBz
O
Me
AnN
NBoc
O
AnN
NBoc
O Ph
4.482
5.574
5.370
7.471
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9
11
10
12
13
SFC
Chiralpak OD-H
15% MeOH
isocratic, 2.5 mL/min
SFC
Chiralpak OJ-H
7% iPrOH
isocratic, 2.5 mL/min
3.737 4.398 92%
7.817 92%
SFC
Chiralpak OD-H
10% iPrOH
isocratic, 2.5 mL/min
SFC
Chiralpak OD-H
15% iPrOH
isocratic, 2.5 mL/min
6.049 5.143 97%
SFC
Chiralpak OD-H
7% iPrOH
isocratic, 2.5 mL/min
10.434 97%
4.429 3.910 93%
Entry Product AssayConditions
Retention time
of major
isomer (min)
Retention time
of minor
isomer (min)
%ee
BzN
NBoc
O OBn
BzN
NBoc
O NHBoc
AnN
NBoc
O NHCbz
AnN
NBoc
O
CN
AnN
NBoc
O
O
8.425
9.712
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BzN
N
Boc
O Ph
BzN
N
Boc
O Et
BzN
N
Boc
O F SFCChiralpak IC
10% iPrOH
isocratic, 2.5 mL/min
BzN
N
Boc
O
CO2Me
BzN
N
Boc
O Me
BzN
N
Boc
O
CN
BzN
N
Boc
O OBn
BzN
N
Boc
O
BzN
N
Boc
O
Cl
SFC
Chiralpak AD-H
10% iPrOH
isocratic, 2.5 mL/min
SFC
Chiralpak IC
30% iPrOH
isocratic, 2.5 mL/min
SFC
Chiralpak IC
20% iPrOH
isocratic, 2.5 mL/min
SFC
Chiralpak OJ-H
7% iPrOH
isocratic, 2.5 mL/min
3.209 2.569 93%
SFC
Chiralpak OJ-H
7% iPrOH
isocratic, 2.5 mL/min
3.956 2.585 94%
SFC
Chiralpak AD-H
10% iPrOH
isocratic, 2.5 mL/min
5.591 6.372 95%
SFC
Chiralpak AD-H
10% iPrOH
isocratic, 2.5 mL/min
4.679 3.777 94%
SFC
Chiralpak IC
20% iPrOH
isocratic, 2.5 mL/min
4.096 4.670 95%
3.148 4.927 74%
5.131 4.419 87%
4.769 4.399 90%
6.226 5.041 92%
Entry Product AssayConditions
Retention time
of major
isomer (min)
Retention time
of minor
isomer (min)
%ee
14
16
17
18
19
20
15
22
21
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Infrared spectrum (Thin Film, NaCl) of compound 2. 
 
 13C NMR (126 MHz, CDCl3) of compound 2. 
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Infrared spectrum (Thin Film, NaCl) of compound SI-3. 
 
 13C NMR (126 MHz, CDCl3) of compound SI-3. 
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Infrared spectrum (Thin Film, NaCl) of compound SI-4. 
 
 13C NMR (126 MHz, CDCl3) of compound SI-4. 
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Infrared spectrum (Thin Film, NaCl) of compound SI-5. 
 
 13C NMR (101 MHz, CDCl3) of compound SI-5. 
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Infrared spectrum (Thin Film, NaCl) of compound SI-6. 
 
 13C NMR (101 MHz, CDCl3) of compound SI-6. 
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Infrared spectrum (Thin Film, NaCl) of compound 3b. 
 13C NMR (101 MHz, CDCl3) of compound 3b. 
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Infrared spectrum (Thin Film, NaCl) of compound 3c. 
 
 13C NMR (126 MHz, CDCl3) of compound 3c. 
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Infrared spectrum (Thin Film, NaCl) of compound 3d. 
 
 13C NMR (101 MHz, CDCl3) of compound 3d. 
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Infrared spectrum (Thin Film, NaCl) of compound 3e. 
 
 13C NMR (101 MHz, CDCl3) of compound 3e. 
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Infrared spectrum (Thin Film, NaCl) of compound 3f. 
 
 13C NMR (101 MHz, CDCl3) of compound 3f. 
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Infrared spectrum (Thin Film, NaCl) of compound 3h. 
 
 13C NMR (101 MHz, CDCl3) of compound 3h. 
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Infrared spectrum (Thin Film, NaCl) of compound 3i. 
 
 13C NMR (126 MHz, CDCl3) of compound 3i. 
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Infrared spectrum (Thin Film, NaCl) of compound 3j. 
 
 13C NMR (101 MHz, CDCl3) of compound 3j. 
 
65
  1 H
 N
M
R
 (4
00
 M
H
z,
 C
D
C
l 3)
 o
f c
om
po
un
d 
3k
. 
 
66
 
 
 
 
Infrared spectrum (Thin Film, NaCl) of compound 3k. 
 
 13C NMR (101 MHz, CDCl3) of compound 3k. 
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Infrared spectrum (Thin Film, NaCl) of compound 3l. 
 
 13C NMR (101 MHz, CDCl3) of compound 3l. 
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Infrared spectrum (Thin Film, NaCl) of compound 3m. 
 
 13C NMR (101 MHz, CDCl3) of compound 3m. 
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Infrared spectrum (Thin Film, NaCl) of compound 4a. 
 
 13C NMR (101 MHz, CDCl3) of compound 4a. 
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Infrared spectrum (Thin Film, NaCl) of compound 4b. 
 
 13C NMR (101 MHz, CDCl3) of compound 4b. 
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Infrared spectrum (Thin Film, NaCl) of compound 4c. 
 
 13C NMR (101 MHz, CDCl3) of compound 4c. 
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Infrared spectrum (Thin Film, NaCl) of compound 4d. 
 
 13C NMR (126 MHz, CDCl3) of compound 4d. 
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Infrared spectrum (Thin Film, NaCl) of compound 4e. 
 
 13C NMR (126 MHz, CDCl3) of compound 4e. 
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Infrared spectrum (Thin Film, NaCl) of compound 4f. 
 
 13C NMR (101 MHz, CDCl3) of compound 4f. 
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Infrared spectrum (Thin Film, NaCl) of compound 4h. 
 
 13C NMR (101 MHz, CDCl3) of compound 4h. 
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Infrared spectrum (Thin Film, NaCl) of compound 4i. 
 
 13C NMR (126 MHz, CDCl3) of compound 4i. 
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Infrared spectrum (Thin Film, NaCl) of compound 4j. 
 
 13C NMR (101 MHz, CDCl3) of compound 4j. 
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Infrared spectrum (Thin Film, NaCl) of compound 4k. 
 
 13C NMR (101 MHz, CDCl3) of compound 4k. 
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Infrared spectrum (Thin Film, NaCl) of compound 4l. 
 
 13C NMR (101 MHz, CDCl3) of compound 4l. 
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Infrared spectrum (Thin Film, NaCl) of compound 4m. 
 
 13C NMR (101 MHz, CDCl3) of compound 4m. 
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Infrared spectrum (Thin Film, NaCl) of compound 5a. 
 
 13C NMR (101 MHz, CDCl3) of compound 5a. 
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Infrared spectrum (Thin Film, NaCl) of compound 5b. 
 
 13C NMR (101 MHz, CDCl3) of compound 5b. 
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Infrared spectrum (Thin Film, NaCl) of compound 5c. 
 
 13C NMR (101 MHz, CDCl3) of compound 5c. 
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Infrared spectrum (Thin Film, NaCl) of compound 5d. 
 
 13C NMR (101 MHz, CDCl3) of compound 5d. 
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Infrared spectrum (Thin Film, NaCl) of compound 5e. 
 
 13C NMR (101 MHz, CDCl3) of compound 5e. 
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Infrared spectrum (Thin Film, NaCl) of compound 5f. 
 
 13C NMR (101 MHz, CDCl3) of compound 5f. 
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Infrared spectrum (Thin Film, NaCl) of compound 5g. 
 
 13C NMR (101 MHz, CDCl3) of compound 5g. 
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Infrared spectrum (Thin Film, NaCl) of compound 5h. 
 
 13C NMR (101 MHz, CDCl3) of compound 5h. 
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Infrared spectrum (Thin Film, NaCl) of compound 5i. 
 
 13C NMR (101 MHz, CDCl3) of compound 5i. 
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Infrared spectrum (Thin Film, NaCl) of compound 6a. 
 
 13C NMR (101 MHz, CDCl3) of compound 6a. 
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Infrared spectrum (Thin Film, NaCl) of compound 6b. 
 
 13C NMR (101 MHz, CDCl3) of compound 6b. 
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Infrared spectrum (Thin Film, NaCl) of compound 6c. 
 
 13C NMR (101 MHz, CDCl3) of compound 6c. 
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Infrared spectrum (Thin Film, NaCl) of compound 6d. 
 
 13C NMR (101 MHz, CDCl3) of compound 6d. 
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Infrared spectrum (Thin Film, NaCl) of compound 6e. 
 
 13C NMR (101 MHz, CDCl3) of compound 6e. 
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Infrared spectrum (Thin Film, NaCl) of compound 6f. 
 
 13C NMR (101 MHz, CDCl3) of compound 6f. 
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Infrared spectrum (Thin Film, NaCl) of compound 6g. 
 
 13C NMR (101 MHz, CDCl3) of compound 6g. 
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Infrared spectrum (Thin Film, NaCl) of compound 6h. 
 
 13C NMR (101 MHz, CDCl3) of compound 6h. 
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Infrared spectrum (Thin Film, NaCl) of compound 6i. 
 
 13C NMR (101 MHz, CDCl3) of compound 6i. 
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Infrared spectrum (Thin Film, NaCl) of compound 8. 
 
 13C NMR (101 MHz, CDCl3) of compound 8. 
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Infrared spectrum (Thin Film, NaCl) of compound 9. 
 
 13C NMR (101 MHz, CDCl3) of compound 9. 
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Infrared spectrum (Thin Film, NaCl) of compound 10. 
 
 13C NMR (101 MHz, CDCl3) of compound 10. 
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Infrared spectrum (Thin Film, NaCl) of compound 11. 
 
 13C NMR (101 MHz, CDCl3) of compound 11. 
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Infrared spectrum (Thin Film, NaCl) of compound 12. 
 
 13C NMR (101 MHz, CDCl3) of compound 12. 
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Infrared spectrum (Thin Film, NaCl) of compound 13. 
 
 13C NMR (101 MHz, CDCl3) of compound 13. 
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Infrared spectrum (Thin Film, NaCl) of compound 14. 
 
 13C NMR (101 MHz, CD3OD) of compound 14. 
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Infrared spectrum (Thin Film, NaCl) of compound 15. 
 
 13C NMR (101 MHz, CD3OD) of compound 15. 
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1H-13C HMBC (CD3OD) of compound 15 
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Infrared spectrum (Thin Film, NaCl) of compound 16. 
 
 13C NMR (101 MHz, CD3OD) of compound 16. 
 
150
	 151	
(4a)	  
 
 
 
 
 
(4b)  
 
 
 
BzN
NBoc
O
AnN
NBoc
O
	 152	
(4c)  
 
 
 
 
 
(4d)  
 
 
 
BzN
NCbz
O
NBoc
O
BzN
Cl
	 153	
(4e)  
 
 
 
 
 
 
 
 
(4f)  
 
 
BzN
NBoc
O
Me
NBoc
O
Me
N
O
MeO
	 154	
 
 
(4g)  
 
 
 
 
 
 
(4h)	  
 
 
BzN
NBz
O
Me
NBoc
O
N
O
MeO
Ph
	 155	
 
 
 
 
 (4i):  
 
 
 
 
 
 
 
 
 
 
 
 
BzN
NBoc
O OBn
	 156	
(4j):  
 
 
 
 
(4k):  
 
 
 
NBoc
O
N
O
MeO
CN
NBoc
O
N
O
MeO
MeO
	 157	
 
 
(4l):  
 
 
 
 
 
(4m)  
 
 
 
NBoc
O
N
O
MeO
NHCbz
BzN
NBoc
O NHBoc
	 158	
 
 
 
(6a):  
 
 
 
 
 
 
 
 
 
 
(6b):  
BzN
N
Boc
O Me
BzN
N
Boc
O Et
	 159	
 
 
 
 
 
(6c):  
 
 
 
 
BzN
N
Boc
O
CO2Me
	 160	
 (6d):  
 
 
 
 
 (6e):  
 
 
 
 
BzN
N
Boc
O
Cl
BzN
N
Boc
O Ph
	 161	
(6f)  
 
 
 
 
 
 
 
 
 
 
(6g)  
 
 
BzN
N
Boc
O
CN
BzN
N
Boc
O OBn
	 162	
 
 
 
(6h)  
 
 
 
 
(6i)  
 
 
BzN
N
Boc
O F
BzN
N
Boc
O
	 163	
		
 
 
 
